

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## The impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023683
Article Type:	Protocol
Date Submitted by the Author:	18-Apr-2018
Complete List of Authors:	<p>Auriacombe, Marc; Univ Bordeaux; SANPSY, CNRS USR 3413, Addiction Team</p> <p>Roux, Perrine; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Vilotitch, Antoine; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Kirchherr, Sébastien; INSERM 1114, University Hospital of Strasbourg, Department of Psychiatry and Addictology</p> <p>Kervran, Charlotte; Univ Bordeaux; SANPSY, CNRS USR 3413, Addiction Team</p> <p>Chauvin, Carole; CERMES3 (INSERM U988/UMR CNRS 8211/EHESS/Paris Descartes University)</p> <p>Gutowski, Marie; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Briand Madrid, Laélia; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Denis, Cécile; SANPSY, CNRS USR 3413, Addiction Team; University of Pennsylvania Center for Studies of Addiction, Department of Psychiatry</p> <p>Carrieri, Maria Patrizia; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Lalanne-Tongio, Laurence; INSERM 1114, University Hospital of Strasbourg, Department of Psychiatry and Addictology; University Hospital of Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Department of Psychiatry and Addictology</p> <p>Jauffret-Roustide, Marie; CERMES3 (INSERM U988/UMR CNRS 8211/EHESS/Paris Descartes University)</p>
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, HIV & AIDS < INFECTIOUS DISEASES, Substance misuse < PSYCHIATRY, PUBLIC HEALTH

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**TITLE :** The impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.

Auriacombe M<sup>\*1,2,3,4</sup>, Roux P<sup>\*5,6</sup>, Vilotitch A<sup>5,6</sup>, Kirchherr S<sup>7</sup>, Kervran C<sup>1,2</sup>, Chauvin C<sup>8</sup>, Gutowski M<sup>5,6</sup>, Briand Madrid L<sup>5,6</sup>, Denis C<sup>2,4</sup>, Carrieri P<sup>5,6</sup>, Lalanne L<sup>\*7,9</sup>, Jauffret-Roustide M<sup>\*8</sup> and the Cosinus group

<sup>1</sup> Univ. Bordeaux, Bordeaux, France

<sup>2</sup> Addiction Team (Laboratoire de psychiatrie) / SANPSY, CNRS USR 3413, Bordeaux, France

<sup>3</sup> Pôle Addictologie, CH Charles Perrens and CHU de Bordeaux, Bordeaux, France

<sup>4</sup> Center for Studies of Addiction, Department of psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

<sup>5</sup> Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France

<sup>6</sup> ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France.

<sup>7</sup> INSERM 1114, Department of Psychiatry and Addictology, University Hospital of Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France.

<sup>8</sup> CERMES3 (Inserm U988/UMR CNRS 8211/EHESS/Paris Descartes University)

<sup>9</sup> Department of Psychiatry and Addictology, University Hospital of Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France.

1  
2  
3 \*equal contribution  
4  
5  
6  
7

8 Corresponding author: Perrine Roux, SESSTIM, IHU Méditerranée Infection, 19-21  
9  
10 boulevard Jean Moulin, 13005 Marseille, France, [perrine.roux@inserm.fr](mailto:perrine.roux@inserm.fr), +334 13 73 22 78  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ABSTRACT

**Introduction:** The high prevalence of hepatitis C and the persistence of HIV and HCV risk practices in people who inject drugs (PWID) in France underlines the need for innovative prevention interventions. The main objective of this article is to describe the design of the COSINUS cohort study and outline which issues it will explore to evaluate the impact of drug consumption rooms (DCR) on PWID outcomes. Secondary objectives are to assess how DCR a) influence other drug-related practices, such as the transition from intravenous to less risky modes of use, b) reduce drug use frequency/quantity, c) increase access to treatment for addiction and comorbidities (infectious, psychiatric and other), d) improve social conditions, and e) reduce levels of violence experienced and drug-related offenses. COSINUS will also give us the opportunity to investigate the impact of other harm reduction tools in France and their combined effect with DCR on reducing HIV-HCV risk practices. Furthermore, we will be better able to identify PWID needs.

**Methods and analysis:** Enrolment in this prospective multisite cohort study started in June 2016. Overall, 680 PWID in 4 different cities (Bordeaux, Marseilles, Paris and Strasbourg) will be enrolled and followed up for 12 months through face-to-face structured interviews administered by trained staff to all eligible participants at baseline (M0), 3-month (M3), 6-month (M6) and 12-month (M12) follow-up visits. These interviews gather data on socio-demographic characteristics, past and current drug and alcohol consumption, drug-use related practices, access to care and social services, experience of violence (as victims), offenses, other psychosocial issues, and perception and needs about harm reduction interventions and services. Longitudinal data analysis will use a mixed logistic model to assess the impact of individual and structural factors, including DCR attendance and exposure to other harm reduction services, on the main outcome (HIV-HCV risk practices).

**Ethics and dissemination:** This study was reviewed and approved by the institutional review

1  
2  
3 board of the French institute of medical research and health (opinion number: 14-166). The  
4 findings of this cohort study will help to assess the impact of DCR on HIV-HCV risk  
5 practices and other psychosocial outcomes and trajectories. Moreover, they will enable health  
6 authorities to shape health and harm reduction policies according to PWID needs. Finally,  
7 they will also help to improve current harm reduction and therapeutic interventions and to  
8 create novel ones.  
9  
10  
11  
12  
13  
14

### 15 16 17 18 **Strengths and limitations of this study**

- 19 • This is the first multisite cohort of PWID conducted in France.
- 20
- 21 • The study's findings will help to assess the impact of DCR and other harm
- 22 reduction services on HIV-HCV risk practices in PWID.
- 23
- 24 • The findings will also assess the needs of PWID in France by providing a
- 25 greater understanding of their social conditions, access to prevention and
- 26 treatment services.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 **Word count:** manuscript = 2523  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

### Rationale

In France, as elsewhere, people who inject drugs (PWID) faced a dramatic HIV epidemic in the 1990s. In response, the French government's harm reduction policy - which first developed programs for access to sterile injection material in 1987 - extended access in 1994 to include syringe vending machines and the sale of ready-to-use injection kits (Steribox®) in community pharmacies<sup>1</sup>, as well as new state-funded needle exchange programs (NEP)<sup>2</sup>. These public health initiatives were concomitant with opiate maintenance treatment (OMT) programs with methadone (available since 1994) and buprenorphine (available since 1995)<sup>3 4</sup> and highly active antiretroviral therapy (HAART) for HIV-infected individuals.<sup>5</sup> HIV prevalence in PWID dramatically decreased from 40% to 20% in 14 years from 1988 to 2002,<sup>2 6</sup> with a prevalence in 2011 of 10%.<sup>7</sup> An estimated 77% to 85% of opioid-dependent individuals in France are currently treated with OMT.<sup>7</sup>

Despite this progress, and just as in many countries where OMT and NEP are available,<sup>8</sup> the impact of this harm reduction policy on the hepatitis C virus (HCV) epidemic in France has not been as great as that for HIV.<sup>2 9-12</sup> This is because this policy was adopted when HCV prevalence was already too high to be rapidly controlled. In 2011, HCV infection prevalence in the country was 64% among many PWID.<sup>7</sup> HCV incidence was also very high, between 11% and 22%,<sup>13</sup> compared with neighboring countries such as the Netherlands.<sup>14</sup> The delay in implementing an efficient harm reduction policy may explain the persistent high national prevalence of HCV in PWID today.<sup>15</sup> Besides HCV and HIV infections, numerous other physical problems can result from injecting drug use, including soft tissue infections,<sup>16 17</sup> cardiovascular and pulmonary complications,<sup>18</sup> and bacterial and fungal infections.<sup>19</sup>

In addition, PWID are more vulnerable to psychiatric comorbidities and precarious socio-economic conditions,<sup>7</sup> to stigma - which is associated with more risk practices - and to lower



1  
2  
3 use of NEP.<sup>11</sup> Because of the increasing amount of available data regarding these elements, a  
4  
5 growing number of studies are exploring the role that social and political environments play  
6  
7 in risk practices, not only for PWID who inject in public, is being increasingly studied, in  
8  
9 order to inform future prevention intervention policies for PWID.<sup>20</sup>

10  
11  
12 Despite the French health authorities' reluctance to open DCR for many years, mostly  
13  
14 because of the country's persistent repressive policy toward drug use and general negative  
15  
16 public opinion,<sup>21</sup> their success in other countries encouraged the French government to  
17  
18 reconsider DCR as a possible additional harm reduction (HR) tool. Two DCR, in Paris and  
19  
20 Strasbourg, were opened in 2016 as part of a 6-year experiment granted on the condition that  
21  
22 the health and social impact of the facilities would be rigorously evaluated. In this perspective,  
23  
24 the COSINUS cohort (COhort to identify Structural and INdividual factors associated with  
25  
26 drug Use) was set up in 2016 to prospectively evaluate the impact of DCR on the reduction of  
27  
28 risk-taking behaviors in PWID.

29  
30  
31 The main objective of this article is to describe the design of the COSINUS cohort study and  
32  
33 outline which issues it will explore to evaluate the impact of the DCR on PWID outcomes.

### 34 35 36 **Research objectives and hypothesis**

37  
38  
39 The main objective of COSINUS is to evaluate the impact of regular DCR use on HIV and  
40  
41 HCV risk practices. The hypothesis is that PWID with regular access to DCR have fewer  
42  
43 practices at risk of HCV and HIV transmission than PWID with no access. It will also  
44  
45 investigate the impact of regular DCR use on access to care. Furthermore, data from  
46  
47 COSINUS will be used to study the impact of other individual (e.g., age, gender, ethnicity,  
48  
49 housing) and structural (e.g., exposure to social services, harm reduction services including  
50  
51 education about safer injection)<sup>22</sup> factors on several outcomes (other risk practices, criminality,  
52  
53 current drug use, negative life events, etc. ). More specifically, it will help provide a greater  
54  
55 understanding of the combined effect of different harm reduction services on PWID health  
56  
57  
58  
59

1  
2  
3 and risk practices.  
4  
5  
6  
7

## 8 **METHODS AND ANALYSIS**

### 9 10 **Study design**

11  
12  
13 This prospective, multicenter cohort study, which started in June 2016, will enroll a total of  
14  
15 680 PWID by October 2017 in 4 different French cities with different geographical and health  
16  
17 characteristics (Bordeaux, Marseilles, Paris and Strasbourg). The study design and data  
18  
19 collection tools were partly inspired by an evaluation of the Vancouver Downtown Eastside  
20  
21 DCR (Insite)<sup>23</sup> and the Vancouver Injection Drug User Study.<sup>24</sup> Individual follow-up will last  
22  
23 12 months. PWID in the DCR in Paris and Strasbourg constitute the “treatment” group  
24  
25 (hereafter “DCR-exposed”), while PWID already enrolled in harm reduction programs in  
26  
27 Bordeaux and Marseilles constitute the “control” group (hereafter “DCR-unexposed”). Data  
28  
29 collection consists in face-to-face interviews (each lasting approximately 20 to 35 minutes)  
30  
31 administered by a trained interviewer at baseline, 3 months, 6 months and 12 months. Data  
32  
33 collection is coordinated by the logistics department of methodology and management (CMG)  
34  
35 of ORS PACA – INSERM-IRD UMR1252 (SESSTIM) in Marseilles, under the supervision  
36  
37 of the cohort’s four PIs (Marc Auriacombe for Bordeaux, Perrine Roux for Marseilles, Marie  
38  
39 Jauffret-Roustide for Paris and Laurence Lalanne-Tongio for Strasbourg), and is managed by  
40  
41 each site-investigator. Participants are compensated for their time with 10 euros worth of  
42  
43 service vouchers after each of the 4 interviews. The study protocol was approved by the  
44  
45 National scientific research ethics committee in Paris (CEEI/IRB).  
46  
47  
48  
49

### 50 **Participants**

51  
52  
53 Subjects are eligible if they are regular users of illegal drugs except cannabis (heroin, cocaine  
54  
55 / crack, amphetamines, ecstasy), and/or prescription drugs (methylphenidate, buprenorphine,  
56  
57  
58  
59  
60

1  
2  
3 benzodiazepines, morphine sulfate, oxycodone, methadone), and have injected drugs at least  
4 once during the previous month. Participants must be over 18 years old and French-speaking.  
5 They must also provide informed consent to participate in the study. To avoid duplicate  
6 enrollment, the month, year and place of birth are recorded for each participant.  
7  
8  
9

## 10 11 **Measures**

12  
13  
14 The evaluation of DCR is based on the following main outcome: the proportion of  
15 participants reporting at least one HCV risk practice (sharing of syringes/needles, sharing of  
16 other injecting paraphernalia (filter, swab, water, cup, etc.)) in the previous month.  
17  
18

19  
20  
21 The other variables that will be collected are: sociodemographic characteristics (gender, age,  
22 housing, employment, living in a couple, ethnicity, parenthood, social allowances, country of  
23 birth); history of drug use (age at first drug use, first injection and related context); current  
24 drug and alcohol use (type, frequency, quantity of drugs used, context of drug use, use  
25 disorder diagnostic criteria, craving); overdoses and suicide risk; drug use-related HIV-HCV  
26 risk practices (injecting, snorting, smoking, sharing and reusing injecting equipment);  
27 addiction treatments; DCR attendance; health conditions and access to care and prevention  
28 (type and frequency of care, satisfaction with care, HIV, HCV and HBV screening, education  
29 in injection, other HR services); criminality (illegal activities and experience of prison);  
30 negative life events (violence, sexual assault, loss of a relative, etc.); psychosocial assessment  
31 (anxiety, ADHD, PTSD, etc.); injection initiation (experience and context); cognitive  
32 assessments (GONOGO, mnesic test); sexual health (sexual risk practices, contraception);  
33 discrimination and life course (parents, childhood).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 This interview questionnaire includes the full version or some items from several already  
51 validated questionnaires as follows: i) the Blood-Borne Virus Transmission Risk Assessment  
52 (BBV-TRAQ)<sup>25</sup> to evaluate the risk practice; ii) a section of the Addiction Severity Index,  
53 which is a multi-dimensional questionnaire which measures drug use based on participants'  
54  
55  
56  
57  
58  
59  
60

self-report;<sup>26 27</sup> iii) the Alcohol Use Disorders Identification Test (AUDIT-C) questionnaire to measure alcohol consumption;<sup>28</sup> iv) a set of questions from the PRIMER study to examine injection initiation;<sup>29</sup> v) three validated questionnaires to measure psychiatric outcomes: the 25-item Wender Utah Rating Scale (WURS) for attention-deficit/hyperactivity disorder screening,<sup>30</sup> the Beck Anxiety Inventory to measure anxiety<sup>31</sup> and the Post-traumatic stress event questionnaire;<sup>32 33</sup> vi) finally, two questionnaires measure participants' cognitive ability: the go-no go task<sup>34</sup> and the mnesic test.<sup>35</sup>

Table 1 displays the schedule for each assessment.

Table 1. Summary of data collection at each follow-up visit

	M0	M3	M6	M12
Socio-demographic characteristics	x	x	x	x
Socio-economic characteristics	x	x	x	x
History of substance use	x			
Current drug use	x	x	x	x
Alcohol and tobacco use	x	x	x	x
Overdoses and suicidal risk	x		x	x
Drug use-related HIV-HCV risk practices	x	x	x	x
Addiction treatment	x	x	x	x
Health conditions and access to care	x		x	x

Screening for HIV and HCV	X		X	X
Criminality	X	X	X	X
Prison experience	X		X	X
Negative life events	X			X
Initiation injection	X		X	X
HR services user satisfaction	X		X	X
Sexual health		X		
Other practices at risk of dermal contamination		X		
DCR attendance and other services	X	X	X	X
Life course		X		
Attention Deficit Hyperactivity Disorder – ADHD		X		
Anxiety: Beck anxiety inventory			X	
Post-traumatic stress disorder			X	
Discrimination		X		
GONOGO Task		X		X
Mnemonic Test		X		X

### Sample size

The main outcome is the comparison of the percentage of PWID reporting at least one HCV risk practice during the previous month between the DCR-exposed and DCR-unexposed groups. The sample size needed was calculated according to this main outcome. Many studies

1  
2  
3 from different countries with DCR have shown that between 30%<sup>36 37</sup> and 60%<sup>38</sup> of users  
4 regularly attend them. In the French context, the proportion of PWID reporting at least one  
5 HCV risk practice varies according to the context and the characteristics of PWID recruited in  
6 different studies, from 25%<sup>22</sup> to 50%<sup>39</sup>. We hypothesize 33% in DCR-exposed participants.  
7  
8 Supposing that one third of participants will regularly attend DCR, with an alpha=5 % and a  
9 power of 80 %, we need a total of 131 participants in each group. Given an expected attrition  
10 rate of 40% after 12 months of follow-up,<sup>40</sup> the sample size is therefore 680 (Paris=250,  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Statistical methods

COSINUS was developed to show the impact of DCR on HIV-HCV risk practices. Longitudinal data analysis will use a mixed logistic model to assess the impact of individual factors (sociodemographic, behavioral and cognitive data) and structural factors, including DCR attendance and exposure to other HR services (access to OMT, social services, education to safer injection, etc.), on the main outcome (reporting at least one HIV-HCV risk practice during the previous month). Data analysis will be carried out with logistic regression models for qualitative data in two ways, multinomial regression for qualitative data of more than two terms, or linear regression for continuous data. A Cox model-based approach (or duration models) will be used to study the impact of DCR attendance (or other HR services) for a certain event at a certain time (transition from injection to another mode of use, access to care). Analyses will be performed using several statistical software packages (SPSS v. 12.0, Intercooled Stata® v. 10.0 and SAS; statistical v 10.0).

### DISCUSSION

The COSINUS cohort study is the first in France designed to assess the impact of DCR on

1  
2  
3 HIV-HCV risk practices. It is important to note that DCR in France are seen as an additional  
4 tool to existing NEP and OMT programs, as well as the recently approved education program  
5 for safer injecting practices.<sup>22</sup>  
6  
7

8  
9  
10 To date, most of the data published on the effects of DCR are from the Vancouver INSITE  
11 research team,<sup>41</sup> whose work greatly contributed to the preliminary design of our cohort study.  
12  
13 However, the French and Vancouver contexts are very different in terms of substances  
14 available on the black market, access to OMT, sharing practices, sero-prevalence of HIV and  
15 HCV, and harm reduction policy. In France, an estimated 180 000 drug users are currently on  
16 OMT,<sup>42</sup> corresponding to an estimated coverage of 80% in urban areas.<sup>7 22</sup> Two thirds of  
17 individuals receiving OMT are treated with buprenorphine. This figure contrasts with other  
18 high-level income countries, where methadone is more accessible.<sup>43</sup> This high coverage of  
19 OMT may have played a role in decreasing long-term HCV prevalence over recent years.<sup>2 9-11</sup>  
20  
21 The decrease in prevalence of HCV has been slower than that seen for HIV. This reflects the  
22 situation in other European countries such as the Netherlands and Switzerland.<sup>44</sup> Overall,  
23 despite high coverage of prevention and treatment services, HCV prevalence data suggest that  
24 PWID – including those receiving OMT<sup>45</sup> - still have a high risk of transmitting HCV.<sup>15 46</sup>  
25  
26 DCR can therefore be an addition to existing HCV prevention tools by engaging difficult-to-  
27 rich PWID in OMT and safer injection practices.  
28  
29

30  
31 Although there are differences between the French and Vancouver contexts in terms of black  
32 market substance abuse (see above), and despite some heterogeneity across and within the  
33 four different metropolitan areas where our study is being conducted,<sup>7</sup> similarities between  
34 the two contexts exist, specifically regarding reduced access to sterile syringes, low  
35 socioeconomic levels, and a high proportion of PWID injecting in public spaces.<sup>7 39</sup>  
36  
37 COSINUS will help us understand the dynamic of HIV-HCV risk practices at a national level,  
38 both in already existing DCR and in sites providing other HR services.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Many prospective studies have tested, evaluated and validated DCR worldwide and have  
4 shown several benefits for public health.<sup>47</sup> Although public opinion on DCR is mixed and has  
5 seen shifting attitudes over time,<sup>21 48</sup> DCR acceptance by drug users and the drug-using  
6 community has been positive to date.<sup>49-52</sup> Any evaluation of DCR needs to take into account  
7 the social environment where DCR are implemented, especially social acceptability by the  
8 neighborhood.<sup>53</sup> DCR facilitate access to needles and provide safer places for users at high  
9 risk both to themselves and to their environment.<sup>38 54 55</sup> They provide hygienic and safe  
10 conditions for intravenous users and staff. They reduce morbidity and mortality associated  
11 with overdoses and with HIV and HCV infections, which is not only beneficial to PWID but  
12 increases healthcare cost-effectiveness.<sup>56</sup> They promote access to opioid dependence  
13 treatment<sup>57</sup> and to prevention interventions related to drug injecting practices.<sup>58 59</sup> However,  
14 few existing DCR provide education programs for safer injection<sup>60</sup> or have a space to inhale  
15 drugs. Moreover, data about the combined effect of DCR with other HR services are sparse.  
16 The Canadian experience has shown the importance of the evaluation process of such a  
17 controversial HR tool.<sup>61 62</sup> More specifically, evidence-based findings from an evaluation  
18 process of the DCR “Insite” helped to advocate against its closure, which was threatened by  
19 the Federal Government.<sup>63</sup> The COSINUS cohort study will not only study the impact of  
20 regularly attendance in DCR on HIV-HCV risk practices in PWID in France, but will also  
21 assess the combined effect of DCR together with other HR services (e.g., education about  
22 safer injection, access to OMT, social activities) on these practices.

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
In addition to evaluating DCR and other HR services, this cohort will be used for a more  
global assessment of the needs of the PWID population in terms of access to treatment for  
addictive disorders. It will also examine the reasons for not seeking treatment, while  
identifying users who may benefit from it. It will help to provide a greater understanding of  
users’ social conditions, practices, their access to prevention and treatment services, and of



1  
2  
3 the role of incarceration and violence in this population often excluded from the health care  
4  
5 system.  
6  
7  
8  
9

## 10 **ETHICS AND DISSEMINATION**

11  
12 This study was approved by the Institutional Review Board (IRB00003888) of the French  
13  
14 institute of medical research and health (opinion number: 14-166). All procedures performed  
15  
16 were in accordance with the 1964 Helsinki declaration and its later amendments. All  
17  
18 participants in the survey gave their informed consent.  
19  
20

21  
22 The results from this cohort will enable health authorities shape health and harm reduction  
23  
24 policies according to PWID needs, as well as improve and create novel harm reduction and  
25  
26 therapeutic interventions. All relevant results will be published in peer-reviewed international  
27  
28 scientific journals and presented at conferences, nationally and internationally.  
29  
30

## 31 **LIST OF ABBREVIATIONS**

32  
33  
34  
35  
36 ADHD: Attention Deficit Hyperactivity Disorder

37  
38  
39 CEEI/IRB: Institutional Review Board

40  
41  
42 CMG: the logistics department of methodology and management

43  
44  
45 COSINUS: COhort to identify Structural and INdividual factors associated with drug Use

46  
47  
48 DCR: Drug Consumption Rooms

49  
50  
51 HBV: Hepatitis B Virus

52  
53  
54 HCV: Hepatitis C Virus

55  
56  
57 HIV: Human Immunodeficiency Virus  
58  
59  
60

1  
2  
3 HR: Harm Reduction

4  
5 INSERM: National Institute of Health and Medical Research

6  
7  
8 NEP: Needle Exchange Programs

9  
10 OMT: Opiate Maintenance Treatment

11  
12  
13 PWID: People Who Inject Drugs

## 14 15 16 17 18 **DECLARATIONS**

### 19 **Authors' contributions**

20  
21  
22  
23 Study conception and design: PC, CD, LL, MA, MJR, PR. Drafting of Manuscript: MA, MJR,  
24 LL, PR, CK, CD drafted the first version of the manuscript. MA, LL, MJR, and PR are the  
25 COSINUS cohort study PIs. SK, LBM, MG, CK, CC are the study-site interviewers and  
26 contributed to improving the design of the study. All authors significantly contributed to the  
27 manuscript and approved the final version.

### 28 **Funding**

29  
30  
31  
32 This work was supported by the French Government Addiction Agency MILDECA (The  
33 inter-ministerial mission to fight against drugs and addictive practices). The funding sponsors  
34 had no role in the design of the study and will have no role in data collection, analysis, or  
35 interpretation of the data. They were not involved in the preparation, review, or approval of  
36 this manuscript.

### 37 **Competing interests**

38  
39  
40  
41 The authors declare that they have nothing to disclose regarding funding or conflict of interest  
42 with respect to this manuscript.

### 43 **Acknowledgements**

Members of the COSINUS scientific committee: Henri-Jean Aubin and Nerkassen Chau (INSERM U669), Pr Jean-Marie Danion (INSERM U1114 and university hospital of Strasbourg), Maurice Dematteis (university hospital of Grenoble), Laurent Karila (INSERM U1000) and Thomas Kerr (British Columbia Centre for Excellence in HIV/AIDS).

## REFERENCES

1. Moatti JP, Vlahov D, Feroni I, et al. Multiple access to sterile syringes for injection drug users: vending machines, needle exchange programs and legal pharmacy sales in Marseille, France. *Eur Addict Res* 2001;7(1):40-5.
2. Fatseas M, Denis C, Serre F, et al. Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy. *AIDS Behav* 2012;16(7):2082-90. doi: 10.1007/s10461-011-0054-4
3. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. *Current psychiatry report* 2007;9(5):358-64.
4. Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. *American Journal of Addiction* 2004;13(1):S17-28.
5. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. *Clin Infect Dis* 2009;49(9):1433-40.
6. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. *Addiction* 2005;100(11):1690-700.
7. Weill-Barillet L, Pillonel J, Semaille C, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. *Rev Epidemiol Sante Publique* 2016 doi: 10.1016/j.respe.2015.10.003
8. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011;378(9791):571-83. doi: S0140-6736(11)61097-0 [pii] 10.1016/S0140-6736(11)61097-0 [published Online First: 2011/08/02]
9. Murray JM, Law MG, Gao Z, et al. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. *Int J Epidemiol* 2003;32(5):708-14.
10. Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. *Aids* 2007;21(14):1967-9.
11. Denis C, Fatseas M, Beltran V, et al. Impact of 20 years harm reduction policy on HIV and HCV among opioid users not in treatment. *Drug and Alcohol Dependence* 2015;146(e261)
12. Jauffret-Roustide M, Emmanuelli J, Quaglia M, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study. *Subst Use Misuse* 2006;41(10-

- 12):1603-21.
13. Leon L, Kasereka S, Barin F, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. *Epidemiol Infect* 2017;145(5):895-907. doi: 10.1017/S0950268816002934
  14. de Vos AS, van der Helm JJ, Matser A, et al. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? *Addiction* 2013;108(6):1070-81. doi: 10.1111/add.12125
  15. Cazein F, Pillonel J, Barin F, et al. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. *AIDS* 2016;30(11):1857-8. doi: 10.1097/QAD.0000000000001115
  16. Kerr T, Wood E, Grafstein E, et al. High rates of primary care and emergency department use among injection drug users in Vancouver. *J Public Health (Oxf)* 2005;27(1):62-6. doi: 10.1093/pubmed/fdh189
  17. Salmon AM, Dwyer R, Jauncey M, et al. Injecting-related injury and disease among clients of a supervised injecting facility. *Drug Alcohol Depend* 2009;101(1-2):132-6. doi: 10.1016/j.drugalcdep.2008.12.002
  18. Dwyer R, Topp L, Maher L, et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. *Drug Alcohol Depend* 2009;100(1-2):9-16. doi: 10.1016/j.drugalcdep.2008.08.016
  19. Palmateer NE, Hope VD, Roy K, et al. Infections with spore-forming bacteria in persons who inject drugs, 2000-2009. *Emerg Infect Dis* 2013;19(1):29-34. doi: 10.3201/eid1901.120044
  20. Rhodes T, Kimber J, Small W, et al. Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. *Addiction* 2006;101(10):1384-93. doi: 10.1111/j.1360-0443.2006.01556.x
  21. Jauffret-Roustide M, Pedrono G, Beltzer N. Supervised consumption rooms: the French Paradox. *Int J Drug Policy* 2013;24(6):628-30. doi: 10.1016/j.drugpo.2013.05.008
  22. Roux P, Le Gall JM, Debrus M, et al. Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study. *Addiction* 2016;111(1):94-106. doi: 10.1111/add.13089
  23. Kerr T, Stoltz JA, Tyndall M, et al. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. *Bmj* 2006;332(7535):220-2.
  24. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. *AIDS* 1997;11(8):F59-65.
  25. Fry CL, Lintzeris N. Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ). *Addiction* 2003;98(2):171-8.
  26. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. *J Subst Abuse Treat* 1992;9(3):199-213.
  27. Denis C, Fatseas M, Beltran V, et al. Usefulness and validity of the modified Addiction Severity Index: A focus on alcohol, drugs, tobacco, and gambling. *Subst Abuse* 2016;37(1):168-75. doi: 10.1080/08897077.2015.1036334
  28. Rubinsky AD, Dawson DA, Williams EC, et al. AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol

- dependence in a U.S. general population sample of drinkers. *Alcohol Clin Exp Res* 2013;37(8):1380-90. doi: 10.1111/acer.12092
29. Werb D, Garfein R, Kerr T, et al. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. *Harm Reduct J* 2016;13(1):25. doi: 10.1186/s12954-016-0114-1
30. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. *Am J Psychiatry* 1993;150(6):885-90. doi: 10.1176/ajp.150.6.885
31. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol* 1988;56(6):893-7.
32. Brunet A, St-Hilaire A, Jehel L, et al. Validation of a French version of the impact of event scale-revised. *Can J Psychiatry* 2003;48(1):56-61. doi: 10.1177/070674370304800111
33. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. *Psychosom Med* 1979;41(3):209-18.
34. Dubois B, Slachevsky A, Litvan I, et al. The FAB: a Frontal Assessment Battery at bedside. *Neurology* 2000;55(11):1621-6.
35. Dubois B, Touchon J, Portet F, et al. ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. *Presse Med* 2002;31(36):1696-9. [published Online First: 2002/12/07]
36. DeBeck K, Kerr T, Bird L, et al. Injection drug use cessation and use of North America's first medically supervised safer injecting facility. *Drug Alcohol Depend* 2011;113(2-3):172-6. doi: 10.1016/j.drugalcdep.2010.07.023
37. Holtzman D, Barry V, Ouellet LJ, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. *Prev Med* 2009;49(1):68-73. doi: 10.1016/j.ypmed.2009.04.014
38. Bravo MJ, Royuela L, De la Fuente L, et al. Use of supervised injection facilities and injection risk behaviours among young drug injectors. *Addiction* 2009;104(4):614-9. doi: 10.1111/j.1360-0443.2008.02474.x
39. Jauffret-Roustide M, Chollet A, Santos A, et al. Theory versus practice, bacteriological efficiency versus personal habits: A bacteriological and user acceptability evaluation of filtering tools for people who inject drugs. *Drug Alcohol Rev* 2017 doi: 10.1111/dar.12564
40. Gindi RM, Rucker MG, Serio-Chapman CE, et al. Utilization patterns and correlates of retention among clients of the needle exchange program in Baltimore, Maryland. *Drug Alcohol Depend* 2009;103(3):93-8. doi: 10.1016/j.drugalcdep.2008.12.018
41. Wood E, Kerr T, Lloyd-Smith E, et al. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. *Harm Reduct J* 2004;1(1):9. doi: 10.1186/1477-7517-1-9
42. Brisacier AC. Tableau de bord « Traitements de substitution aux opiacés ». Saint-Denis: OFDT, 2015.
43. Carrieri MP, Amass L, Lucas GM, et al. Buprenorphine use: the international experience. *Clin Infect Dis* 2006;43 Suppl 4:S197-215. doi: 10.1086/508184
44. van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. *Eur J Epidemiol* 2007;22(3):183-93. doi: 10.1007/s10654-006-9089-7
45. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.



- 1  
2  
3 *BMJ* 2012;345:e5945. doi: 10.1136/bmj.e5945
- 4 46. Jauffret-Roustide M, Le Strat Y, Couturier E, et al. A national cross-sectional study  
5 among drug-users in France: epidemiology of HCV and highlight on practical  
6 and statistical aspects of the design. *BMC Infect Dis* 2009;9:113.
- 7 47. Potier C, Laprevote V, Dubois-Arber F, et al. Supervised injection services: what has  
8 been demonstrated? A systematic literature review. *Drug Alcohol Depend*  
9 2014;145:48-68. doi: 10.1016/j.drugalcdep.2014.10.012
- 10 48. Strike C, Jairam JA, Kolla G, et al. Increasing public support for supervised  
11 injection facilities in Ontario, Canada. *Addiction* 2014;109(6):946-53. doi:  
12 10.1111/add.12506
- 13 49. De Jong W, Weber U. The professional acceptance of drug use: a closer look at  
14 drug consumption rooms in the Netherlands, Germany and Switzerland.  
15 *International Journal of Drug Policy* 1999;10:99-108.
- 16 50. Strike C, Watson TM, Kolla G, et al. Ambivalence about supervised injection  
17 facilities among community stakeholders. *Harm Reduct J* 2015;12:26. doi:  
18 10.1186/s12954-015-0060-3
- 19 51. Salmon AM, Thein HH, Kimber J, et al. Five years on: what are the community  
20 perceptions of drug-related public amenity following the establishment of the  
21 Sydney Medically Supervised Injecting Centre? *Int J Drug Policy* 2007;18(1):46-  
22 53. doi: 10.1016/j.drugpo.2006.11.010
- 23 52. Kral AH, Wenger L, Carpenter L, et al. Acceptability of a safer injection facility  
24 among injection drug users in San Francisco. *Drug Alcohol Depend* 2010;110(1-  
25 2):160-3. doi: 10.1016/j.drugalcdep.2010.02.009
- 26 53. Jauffret-Roustide M. Les salles de consommation à moindre risque : apprendre à  
27 vivre avec les drogues. *Esprit* 2016;429:115-23.
- 28 54. Kerr T, Tyndall MW, Zhang R, et al. Circumstances of first injection among illicit  
29 drug users accessing a medically supervised safer injection facility. *Am J Public*  
30 *Health* 2007;97(7):1228-30. doi: 10.2105/AJPH.2006.086256
- 31 55. Reddon H, Wood E, Tyndall M, et al. Use of North America's first medically  
32 supervised safer injecting facility among HIV-positive injection drug users. *AIDS*  
33 *Educ Prev* 2011;23(5):412-22. doi: 10.1521/aeap.2011.23.5.412
- 34 56. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection  
35 facility. *CMAJ* 2008;179(11):1143-51. doi: 10.1503/cmaj.080808
- 36 57. Wood E, Tyndall MW, Zhang R, et al. Attendance at supervised injecting facilities  
37 and use of detoxification services. *N Engl J Med* 2006;354(23):2512-4. doi:  
38 10.1056/NEJMc052939
- 39 58. Small W, Wood E, Lloyd-Smith E, et al. Accessing care for injection-related  
40 infections through a medically supervised injecting facility: a qualitative study.  
41 *Drug Alcohol Depend* 2008;98(1-2):159-62. doi: 10.1016/j.drugalcdep.2008.05.014
- 42 59. Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the  
43 use of a medically supervised safer injection facility. *J Public Health (Oxf)*  
44 2007;29(1):35-9.
- 45 60. Rachlis B, Lloyd-Smith E, Small W, et al. Harmful microinjecting practices among a  
46 cohort of injection drug users in Vancouver Canada. *Subst Use Misuse*  
47 2010;45(9):1351-66. doi: 10.3109/10826081003767643
- 48 61. Wood RA, Wood E, Lai C, et al. Nurse-delivered safer injection education among a  
49 cohort of injection drug users: evidence from the evaluation of Vancouver's  
50 supervised injection facility. *Int J Drug Policy* 2008;19(3):183-8.
- 51 62. Hyshka E, Bubela T, Wild TC. Prospects for scaling-up supervised injection facilities  
52 in Canada: the role of evidence in legal and political decision-making. *Addiction*  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

2013;108(3):468-76. doi: 10.1111/add.12064

63. Small D. Canada's highest court unchains injection drug users; implications for harm reduction as standard of healthcare. *Harm Reduct J* 2012;9:34. doi: 10.1186/1477-7517-9-34

For peer review only

# BMJ Open

## The impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023683.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Sep-2018
Complete List of Authors:	<p>Auriacombe, Marc; Univ Bordeaux; SANPSY, CNRS USR 3413, Addiction Team</p> <p>Roux, Perrine; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Briand Madrid, Laélia; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Kirchherr, Sébastien; INSERM 1114, University Hospital of Strasbourg, Department of Psychiatry and Addictology</p> <p>Kervran, Charlotte; Univ Bordeaux; SANPSY, CNRS USR 3413, Addiction Team</p> <p>Chauvin, Carole; CERMES3 (INSERM U988/UMR CNRS 8211/EHESS/Paris Descartes University)</p> <p>Gutowski, Marie; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Denis, Cécile; SANPSY, CNRS USR 3413, Addiction Team; University of Pennsylvania Center for Studies of Addiction, Department of Psychiatry</p> <p>Carrieri, Maria Patrizia; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Lalanne, Laurence; INSERM U1114; Hopitaux universitaires de Strasbourg, Department of Psychiatry and Addictology</p> <p>Jauffret-Roustide, Marie; CERMES3 (INSERM U988/UMR CNRS 8211/EHESS/Paris Descartes University)</p> <p>COSINUS, Study Group</p>
<b>Primary Subject Heading</b>:	Addiction
Secondary Subject Heading:	Health policy
Keywords:	supervised injection facility, risk practices, hepatitis C, longitudinal study, injection, harm reduction



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**TITLE :** The impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.

Auriacombe M<sup>\*1,2,3,4</sup>, Roux P<sup>\*5,6</sup>, Briand Madrid L<sup>5,6</sup>, Kirchherr S<sup>7</sup>, Kervran C<sup>1,2</sup>, Chauvin C<sup>8</sup>, Gutowski M<sup>5,6</sup>, Denis C<sup>2,4</sup>, Carrieri MP<sup>5,6</sup>, Lalanne L<sup>\*7,9</sup>, Jauffret-Roustide M<sup>\*8</sup> and the Cosinus study group

<sup>1</sup> Univ. Bordeaux, Bordeaux, France

<sup>2</sup> Addiction Team (Laboratoire de psychiatrie) / SANPSY, CNRS USR 3413, Bordeaux, France

<sup>3</sup> Pôle Addictologie, CH Charles Perrens and CHU de Bordeaux, Bordeaux, France

<sup>4</sup> Center for Studies of Addiction, Department of psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

<sup>5</sup> Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France

<sup>6</sup> ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France.

<sup>7</sup> INSERM 1114, Department of Psychiatry and Addictology, University Hospital of Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France.

<sup>8</sup> CERMES3 (Inserm U988/UMR CNRS 8211/EHESS/Paris Descartes University), Paris, France.

<sup>9</sup> Department of Psychiatry and Addictology, University Hospital of Strasbourg, Fédération de

1  
2  
3 Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France.  
4

5 \*equal contribution  
6  
7  
8  
9

10 Corresponding author: Perrine Roux, SESSTIM, IHU Méditerranée Infection, 19-21  
11  
12 boulevard Jean Moulin, 13005 Marseille, France, [perrine.roux@inserm.fr](mailto:perrine.roux@inserm.fr), +334 13 73 22 78  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** The high prevalence of hepatitis C and the persistence of HIV and HCV risk practices in people who inject drugs (PWID) in France underlines the need for innovative prevention interventions. The main objective of this article is to describe the design of the COSINUS cohort study and outline which issues it will explore to evaluate the impact of drug consumption rooms (DCR) on PWID outcomes. Secondary objectives are to assess how DCR a) influence other drug-related practices, such as the transition from intravenous to less risky modes of use, b) reduce drug use frequency/quantity, c) increase access to treatment for addiction and comorbidities (infectious, psychiatric and other), d) improve social conditions, and e) reduce levels of violence experienced and drug-related offenses. COSINUS will also give us the opportunity to investigate the impact of other harm reduction tools in France and their combined effect with DCR on reducing HIV-HCV risk practices. Furthermore, we will be better able to identify PWID needs.

**Methods and analysis:** Enrolment in this prospective multisite cohort study started in June 2016. Overall, 680 PWID in 4 different cities (Bordeaux, Marseilles, Paris and Strasbourg) will be enrolled and followed up for 12 months through face-to-face structured interviews administered by trained staff to all eligible participants at baseline (M0), 3-month (M3), 6-month (M6) and 12-month (M12) follow-up visits. These interviews gather data on socio-demographic characteristics, past and current drug and alcohol consumption, drug-use related practices, access to care and social services, experience of violence (as victims), offenses, other psychosocial issues, and perception and needs about harm reduction interventions and services. Longitudinal data analysis will use a mixed logistic model to assess the impact of individual and structural factors, including DCR attendance and exposure to other harm reduction services, on the main outcome (HIV-HCV risk practices).

**Ethics and dissemination:** This study was reviewed and approved by the institutional review

1  
2  
3 board of the French institute of medical research and health (opinion number: 14-166). The  
4 findings of this cohort study will help to assess the impact of DCR on HIV-HCV risk  
5 practices and other psychosocial outcomes and trajectories. Moreover, they will enable health  
6 authorities to shape health and harm reduction policies according to PWID needs. Finally,  
7 they will also help to improve current harm reduction and therapeutic interventions and to  
8 create novel ones.  
9  
10  
11  
12  
13  
14

### 15 16 17 18 **Strengths and limitations of this study**

- 19 • This is the first multisite cohort of PWID conducted in France.
- 20
- 21 • The study's findings will help to assess the impact of DCR and other harm  
22 reduction services on HIV-HCV risk practices in PWID.
- 23
- 24 • The findings will also assess the needs of PWID in France by providing a  
25 greater understanding of their social conditions, access to prevention and  
26 treatment services.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 **Word count:** manuscript = 2870  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

### Rationale

In France, as elsewhere, people who inject drugs (PWID) faced a dramatic HIV epidemic in the 1990s. In response, the French government's harm reduction policy - which first developed programs for access to sterile injection material in 1987 - extended access in 1994 to include syringe vending machines and the sale of ready-to-use injection kits (Steribox®) in community pharmacies<sup>1</sup>, as well as new state-funded needle exchange programs (NEP)<sup>2</sup>. These public health initiatives were concomitant with opiate maintenance treatment (OMT) programs with methadone (available since 1994) and buprenorphine (available since 1995)<sup>3,4</sup> and highly active antiretroviral therapy (HAART) for HIV-infected individuals.<sup>5</sup> HIV prevalence in PWID dramatically decreased from 40% to 20% in 14 years from 1988 to 2002,<sup>2,6</sup> with a prevalence in 2011 of 10%.<sup>7</sup> An estimated 77% to 85% of opioid-dependent individuals in France are currently treated with OMT.<sup>7</sup>

Despite this progress, and just as in many countries where OMT and NEP are available,<sup>8</sup> the impact of this harm reduction policy on the hepatitis C virus (HCV) epidemic in France has not been as great as that for HIV.<sup>2,9-12</sup> This is because this policy was adopted when HCV prevalence was already too high to be rapidly controlled. In 2011, HCV infection prevalence in the country was 64% among many PWID.<sup>7</sup> HCV incidence was also very high, between 11% and 22%,<sup>13</sup> compared with neighboring countries such as the Netherlands.<sup>14</sup> The delay in implementing an efficient harm reduction policy may explain the persistent high national prevalence of HCV in PWID today.<sup>15</sup> Besides HCV and HIV infections, numerous other physical problems can result from injecting drug use, including soft tissue infections,<sup>16,17</sup> cardiovascular and pulmonary complications,<sup>18</sup> and bacterial and fungal infections.<sup>19</sup> In addition, research on existing drug consumption rooms (DCR) showed that they improve access to primary health care and improve safer injection conditions.<sup>20</sup> By attracting the most

1  
2  
3 marginalized PWID,<sup>21</sup> they also reduce the level of public injection and so the number of used  
4 syringes has dropped in public spaces.<sup>22</sup> Finally, it has also been shown that DCR are  
5 effective in reducing fatal overdoses.<sup>23</sup>  
6  
7

8  
9  
10 Despite the French health authorities' reluctance to open DCR for many years, mostly  
11 because of the country's persistent repressive policy toward drug use and general negative  
12 public opinion,<sup>24</sup> their success in other countries encouraged the French government to  
13 reconsider DCR as a possible additional harm reduction (HR) tool. Two DCR, in Paris and  
14 Strasbourg, were opened in 2016 as part of a 6-year experiment granted on the condition that  
15 the health and social impact of the facilities would be rigorously evaluated. These two DCR  
16 accept all PWID 18 years or older and provide the following services: the possibility to  
17 administer drugs by injection (or inhalation in some cases, only for PWID), access to social,  
18 medical and psychiatric consultations, the provision of sterile equipment, the collection and  
19 disposal of used injection equipment, primary care, harm reduction counselling and HCV,  
20 HBV and HIV testing. In this perspective, the COSINUS cohort (COhort to identify  
21 Structural and INdividual factors associated with drug Use) was set up in 2016 to  
22 prospectively evaluate the impact of DCR on the reduction of risk-taking behaviors in PWID.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 The main objective of this article is to describe the design of the COSINUS cohort study and  
39 outline which issues it will explore to evaluate the impact of the DCR on PWID outcomes.  
40  
41  
42

#### 43 Research objectives and hypothesis

44  
45 The main objective of COSINUS is to evaluate the impact of regular DCR use on HIV and  
46 HCV risk practices. The hypothesis is that PWID with regular access to DCR have fewer  
47 practices at risk of HCV and HIV transmission than PWID with no access. It will also  
48 investigate the impact of regular DCR use on access to care. Furthermore, data from  
49 COSINUS will be used to study the impact of other individual (e.g., age, gender, ethnicity,  
50 housing) and structural (e.g., exposure to social services, harm reduction services including  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 education about safer injection)<sup>25</sup> factors on several outcomes (other risk practices, criminality,  
4 current drug use, negative life events, etc. ). More specifically, it will help provide a greater  
5 understanding of the combined effect of different harm reduction services on PWID health  
6 and risk practices.  
7  
8  
9

## 10 11 12 13 14 METHODS AND ANALYSIS

### 15 16 17 Study design

18  
19 This prospective, multicenter cohort study, which started in June 2016, will enroll a total of  
20 680 PWID by October 2017 in 4 different French cities with different geographical and health  
21 characteristics (Bordeaux, Marseilles, Paris and Strasbourg). The study design and data  
22 collection tools were partly inspired by an evaluation of the Vancouver Downtown Eastside  
23 DCR (Insite)<sup>26</sup> and the Vancouver Injection Drug User Study.<sup>27</sup> Individual follow-up will last  
24 12 months. PWID in the DCR in Paris and Strasbourg constitute the “treatment” group  
25 (hereafter “DCR-exposed”), while PWID already enrolled in harm reduction programs  
26 constitute the “control” group (hereafter “DCR-unexposed”). These four cities were chosen  
27 because they were all candidates for the opening of DCR when the law permitting  
28 experimentation with DCR passed (Public Health Law from January 2016). Data collection  
29 consists in face-to-face interviews (each lasting approximately 20 to 35 minutes) administered  
30 by a trained interviewer at baseline, 3 months, 6 months and 12 months. Data collection is  
31 coordinated by the logistics department of methodology and management (CMG) of ORS  
32 PACA – INSERM-IRD UMR1252 (SESSTIM) in Marseilles, under the supervision of the  
33 cohort’s four PIs (Marc Auriacombe for Bordeaux, Perrine Roux for Marseilles, Marie  
34 Jauffret-Roustide for Paris and Laurence Lalanne-Tongio for Strasbourg), and is managed by  
35 each site-investigator. Participants are compensated for their time with 10 euros worth of  
36 service vouchers after each of the 4 interviews. The study protocol was approved by the  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Institutional Review Board (IRB00003888) of the French institute of medical research and  
4 health (opinion number: 14-166).  
5

## 6 7 Participants

8  
9  
10 Subjects were eligible if they reported injecting illicit drugs except cannabis (heroin, cocaine /  
11 crack, amphetamines, ecstasy), and/or prescription drugs (methylphenidate, buprenorphine,  
12 benzodiazepines, morphine sulphate, oxycodone, methadone) at least once during the  
13 previous month. Participants must be over 18 years old and French-speaking. They must also  
14 provide informed consent to participate in the study. They were recruited mainly in the DCR  
15 (in the cities where there is one) and in other harm reduction facilities that currently outreach  
16 to PWID likely to attend a DCR if available in each city. This mix of recruitment sites was  
17 chosen in order to be able to compare PWID between cities. To avoid duplicate enrollment,  
18 the month, year and place of birth are recorded for each participant.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 Measures

31  
32 The evaluation of DCR is based on the following main outcome: the proportion of  
33 participants reporting at least one injection-related HIV-HCV risk practice (sharing of  
34 syringes/needles, sharing of other injecting paraphernalia (filter, swab, water, cup, etc.)) in the  
35 previous month.  
36  
37  
38  
39  
40

41  
42 The other variables that will be collected are: sociodemographic characteristics (gender, age,  
43 housing, employment, living in a couple, ethnicity, parenthood, social allowances, country of  
44 birth); history of drug use (age at first drug use, first injection and related context); current  
45 drug and alcohol use (type, frequency, quantity of drugs used, context of drug use, use  
46 disorder diagnostic criteria, craving); overdoses and suicide risk; drug use-related HIV-HCV  
47 risk practices (injecting, snorting, smoking, sharing and reusing injecting equipment);  
48 addiction treatments; DCR attendance; health conditions and access to care and prevention  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(type and frequency of care, satisfaction with care, HIV, HCV and HBV screening and self-reported HIV and HCV status, education in injection, other HR services); criminality (illegal activities and experience of prison); negative life events (violence, sexual assault, loss of a relative, etc.); psychosocial assessment (anxiety, ADHD, PTSD, etc.); injection initiation (experience and context); cognitive assessments (GONOGO, mnesic test); sexual health (sexual risk practices, contraception); discrimination and life course (parents, childhood).

This interview questionnaire includes the full version or some items from several already validated questionnaires as follows: i) the Blood-Borne Virus Transmission Risk Assessment (BBV-TRAQ)<sup>28</sup> to evaluate the risk practice; ii) a section of the Addiction Severity Index, which is a multi-dimensional questionnaire which measures drug use based on participants' self-report;<sup>29 30</sup> iii) the Alcohol Use Disorders Identification Test (AUDIT-C) questionnaire to measure alcohol consumption;<sup>31</sup> iv) a set of questions from the PRIMER study to examine injection initiation;<sup>32</sup> v) three validated questionnaires to measure psychiatric outcomes: the 25-item Wender Utah Rating Scale (WURS) for attention-deficit/hyperactivity disorder screening,<sup>33</sup> the Beck Anxiety Inventory to measure anxiety<sup>34</sup> and the Post-traumatic stress event questionnaire;<sup>35 36</sup> vi) finally, two questionnaires measure participants' cognitive ability: the go-no go task<sup>37</sup> and the mnesic test.<sup>38</sup>

Table 1 displays the schedule for each assessment.

Table 1. Summary of data collection at each follow-up visit

	M0	M3	M6	M12

Socio-demographic characteristics	X	X	X	X
Socio-economic characteristics	X	X	X	X
History of substance use	X			
Current drug use	X	X	X	X
Alcohol and tobacco use	X	X	X	X
Overdoses and suicidal risk	X		X	X
Drug use-related HIV-HCV risk practices	X	X	X	X
Addiction treatment	X	X	X	X
Health conditions and access to care	X		X	X
Screening for HIV and HCV	X		X	X
Criminality	X	X	X	X
Prison experience	X		X	X
Negative life events	X			X
Initiation injection	X		X	X
HR services user satisfaction	X		X	X
Sexual health		X		
Other practices at risk of dermal contamination		X		
DCR attendance and other services	X	X	X	X
Life course		X		
Attention Deficit Hyperactivity Disorder – ADHD		X		

Anxiety: Beck anxiety inventory			X	
Post-traumatic stress disorder			X	
Discrimination		X		
GONOGO Task		X		X
Mnemonic Test		X		X

### Sample size

The main outcome is the comparison of the percentage of PWID reporting at least one injection-related HIV-HCV risk practice during the previous month between the DCR-exposed and DCR-unexposed groups. The sample size needed was calculated according to this main outcome. Many studies from different countries with DCR have shown that between 30%<sup>39 40</sup> and 60%<sup>41</sup> of users regularly attend them (at least once a week). In the French context, the proportion of PWID reporting at least one injection-related HIV-HCV risk practice varies according to the context and the characteristics of PWID recruited in different studies, from 25%<sup>25</sup> to 50%<sup>42</sup>. We hypothesize 33% of regular (i.e., at least once a week) DCR attending participants will report at least one of these events. Supposing that one third of participants will regularly attend DCR, with an alpha=5 % and a power of 80 %, we need a total of 131 participants in each group. Given an expected attrition rate of 40% after 12 months of follow-up,<sup>43</sup> the sample size is therefore 680 (Paris=250, Marseilles=200, Bordeaux=150, Strasbourg=80).

### Statistical methods

COSINUS was developed to show the impact of DCR on HIV-HCV risk practices.

Longitudinal data analysis will use a mixed logistic model to assess the impact of individual

1  
2  
3 factors (sociodemographic, behavioral and cognitive data) and structural factors, including  
4 DCR attendance and exposure to other HR services (access to OMT, social services,  
5 education to safer injection, etc.), on the main outcome (reporting at least one injection-  
6 related HIV-HCV risk practice during the previous month). Data analysis will be carried out  
7 with logistic regression models for qualitative data in two ways, multinomial regression for  
8 qualitative data of more than two terms, or linear regression for continuous data. In addition,  
9 to study the impact of the combined effect of different services (DCR, education about safe  
10 injection, other HR services) on the main outcome, we will use mixed-model regression  
11 analysis by adjusting for these different structural factors and other covariates. A Cox model-  
12 based approach (or duration models) will be used to study the impact of DCR attendance (or  
13 other HR services) for a certain event at a certain time (transition from injection to another  
14 mode of use, access to care). To take into account bias due to missing data and loss to follow-  
15 up, we will perform sensitivity analyses using the Heckman model, which adjusts for this  
16 potential source of statistical bias.<sup>44</sup> Analyses will be performed using several statistical  
17 software packages (SPSS v. 12.0, Intercooled Stata® v. 10.0 and SAS; statistical v 10.0).

### 35 Patient and Public Involvement

36 Although participants did not directly contribute to the design of the study or to the  
37 development of the research questions, their needs and preferences were considered  
38 throughout the process. Feedback to the participants regarding scientific results, will be  
39 organized on each study site.

## 50 DISCUSSION

51  
52 The COSINUS cohort study is the first in France designed to assess the impact of DCR on  
53 HIV-HCV risk practices. It is important to note that DCR in France are seen as an additional  
54

1  
2  
3 tool to existing NEP and OMT programs, as well as the recently education program for safer  
4 injecting practices.<sup>25</sup>  
5  
6

7  
8 To date, most of the data published on the effects of DCR are from the Vancouver INSITE  
9 research team,<sup>45</sup> whose work greatly contributed to the preliminary design of our cohort study.  
10  
11 However, the French and Vancouver contexts are very different in terms of substances  
12 available on the black market, access to OMT, sharing practices, sero-prevalence of HIV and  
13 HCV, and harm reduction policy. In France, an estimated 180 000 drug users are currently on  
14 OMT,<sup>46</sup> corresponding to an estimated coverage of 80% in urban areas.<sup>7 25</sup> Two thirds of  
15 individuals receiving OMT are treated with buprenorphine. This figure contrasts with other  
16 high-level income countries, where methadone is more accessible.<sup>47</sup> This high coverage of  
17 OMT may have played a role in decreasing long-term HCV prevalence over recent years.<sup>29-11</sup>  
18  
19 The decrease in prevalence of HCV has been slower than that seen for HIV. This reflects the  
20 situation in other European countries such as the Netherlands and Switzerland.<sup>48</sup> Overall,  
21 despite high coverage of prevention and treatment services, HCV prevalence data suggest that  
22 PWID – including those receiving OMT<sup>49</sup> - still have a high risk of transmitting HCV.<sup>15 50</sup>  
23  
24 DCR can therefore be an addition to existing HCV prevention tools by engaging difficult-to-  
25 rich PWID in OMT and safer injection practices.  
26  
27

28  
29 Although there are differences between the French and Vancouver contexts in terms of black  
30 market substance abuse (see above), and despite some heterogeneity across and within the  
31 four different metropolitan areas where our study is being conducted,<sup>7</sup> similarities between  
32 the two contexts exist, specifically regarding reduced access to sterile syringes, low  
33 socioeconomic levels, and a high proportion of PWID injecting in public spaces.<sup>7 42</sup>  
34  
35 COSINUS will help us understand the dynamic of HIV-HCV risk practices at a national level,  
36 both in already existing DCR and in sites providing other HR services. In France, incidence of  
37 fatal overdoses among PWID is low, making it difficult to reduce it significantly over a 12-  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 month period. This could be related to the national harm reduction policy implemented in the  
4  
5 1990s including access to OST<sup>6</sup> and a high level of OST coverage.<sup>7 46</sup>  
6

7  
8 Many prospective studies have tested, evaluated and validated DCR worldwide and have  
9  
10 shown several benefits for public health.<sup>20</sup> Although public opinion on DCR is mixed and has  
11  
12 seen shifting attitudes over time,<sup>24 51</sup> DCR acceptance by drug users and the drug-using  
13  
14 community has been positive to date.<sup>52-55</sup> Any evaluation of DCR needs to take into account  
15  
16 the social environment where DCR are implemented, especially social acceptability by the  
17  
18 neighborhood.<sup>56</sup> DCR facilitate access to needles and provide safer places for users at high  
19  
20 risk both to themselves and to their environment.<sup>41 57 58</sup> They provide hygienic and safe  
21  
22 conditions for intravenous users and staff. They reduce morbidity and mortality associated  
23  
24 with overdoses and with HIV and HCV infections, which is not only beneficial to PWID but  
25  
26 increases healthcare cost-effectiveness.<sup>59</sup> They promote access to opioid dependence  
27  
28 treatment<sup>60</sup> and to prevention interventions related to drug injecting practices.<sup>61 62</sup> However,  
29  
30 few existing DCR provide education programs for safer injection<sup>63</sup> or have a space to inhale  
31  
32 drugs. Moreover, data about the combined effect of DCR with other HR services are sparse.  
33  
34 The Canadian experience has shown the importance of the evaluation process of such a  
35  
36 controversial HR tool.<sup>64 65</sup> More specifically, evidence-based findings from an evaluation  
37  
38 process of the DCR “Insite” helped to advocate against its closure, which was threatened by  
39  
40 the Federal Government.<sup>66</sup> The COSINUS cohort study will not only study the impact of  
41  
42 regularly attendance in DCR on HIV-HCV risk practices in PWID in France, but will also  
43  
44 assess the combined effect of DCR together with other HR services (e.g., education about  
45  
46 safer injection, access to OMT, social activities) on these practices.  
47  
48  
49

50  
51 Some limitations have to be acknowledged. First, all the data collected were self-reported.

52  
53 Although the use of self-reports may be subject to social desirability bias, studies have shown  
54  
55 their reliability in drug-using populations.<sup>67 68</sup> To control any such bias, we used trained  
56  
57  
58  
59  
60

1  
2  
3 interviewers independent of the participating harm reduction facilities. In terms of the  
4 diversity of our sample, all the PWID were recruited through easily accessible harm reduction  
5 facilities which conduct outreach actions, and which constitute the main contact that the  
6 PWID population has with the health care system. Another limitation is that, due to cost  
7 limitations of our study, we enrolled only French-speaking participants. Further studies are  
8 planned to better investigate the impact of DCRs in all the population of PWID including non  
9 French-speaking PWID that represent around 20% of people who attend DCRs.<sup>69</sup>

10  
11 In addition to evaluating DCR and other HR services, this cohort will be used for a more  
12 global assessment of the needs of the PWID population in terms of access to treatment for  
13 addictive disorders. It will also examine the reasons for not seeking treatment, while  
14 identifying users who may benefit from it. It will help to provide a greater understanding of  
15 users' social conditions, practices, their access to prevention and treatment services, and of  
16 the role of incarceration and violence in this population often excluded from the health care  
17 system.

## 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

### ETHICS AND DISSEMINATION

This study was approved by the Institutional Review Board (IRB00003888) of the French institute of medical research and health (opinion number: 14-166). All procedures performed were in accordance with the 1964 Helsinki declaration and its later amendments. All participants in the survey gave their informed consent.

The results from this cohort will enable health authorities shape health and harm reduction policies according to PWID needs, as well as improve and create novel harm reduction and therapeutic interventions. All relevant results will be published in peer-reviewed international scientific journals and presented at conferences, nationally and internationally.



1  
2  
3  
4  
5 LIST OF ABBREVIATIONS  
6

7  
8 ADHD: Attention Deficit Hyperactivity Disorder  
9

10  
11 CEEI/IRB: Institutional Review Board  
12

13  
14 CMG: the logistics department of methodology and management  
15

16  
17 COSINUS: COhort to identify Structural and INdividual factors associated with drug Use  
18

19  
20 DCR: Drug Consumption Rooms  
21

22  
23 HBV: Hepatitis B Virus  
24

25  
26 HCV: Hepatitis C Virus  
27

28  
29 HIV: Human Immunodeficiency Virus  
30

31  
32 HR: Harm Reduction  
33

34  
35 INSERM: National Institute of Health and Medical Research  
36

37  
38 NEP: Needle Exchange Programs  
39

40  
41 OMT: Opiate Maintenance Treatment  
42

43  
44 PWID: People Who Inject Drugs  
45

46  
47 DECLARATIONS  
48

49  
50 Authors' contributions  
51

52  
53 Study conception and design: PC, CD, LL, MA, MJR, PR. Drafting of Manuscript: MA, MJR,  
54

55  
56 LL, PR, CK, CD drafted the first version of the manuscript. MA, LL, MJR, and PR are the  
57

58  
59 COSINUS cohort study PIs. SK, LBM, MG, CK, CC are the study-site interviewers and  
60

1  
2  
3 contributed to improving the design of the study. All authors significantly contributed to the  
4  
5 manuscript and approved the final version.  
6

7  
8 The Cosinus study group has contributed to the design and/or the monitoring of the cohort:  
9  
10 Auriacombe M, Bertoia G, Briand Madrid L, Carrieri MP, Célérier I, Chauvin C, Danion JM,  
11  
12 Denis C, Grelli N, Gutowski M, Hamelin N, Jauffret-Roustide M, Kervran C, Kirchherr S,  
13  
14 Lalanne L, Le Breton M, Roux P, Vilotitch A.  
15

### 16 17 Funding

18  
19 This work was supported by the French Government Addiction Agency MILDECA (The  
20  
21 inter-ministerial mission to fight against drugs and addictive practices). The funding sponsors  
22  
23 had no role in the design of the study and will have no role in data collection, analysis, or  
24  
25 interpretation of the data. They were not involved in the preparation, review, or approval of  
26  
27 this manuscript.  
28

### 29 30 Competing interests

31  
32  
33 The authors declare that they have nothing to disclose regarding funding or conflict of interest  
34  
35 with respect to this manuscript.  
36

### 37 38 Acknowledgements

39  
40 Members of the COSINUS scientific committee: Henri-Jean Aubin and Nerkassen Chau  
41  
42 (INSERM U669), Pr Jean-Marie Danion (INSERM U1114 and university hospital of  
43  
44 Strasbourg), Maurice Dematteis (university hospital of Grenoble), Laurent Karila (INSERM  
45  
46 U1000) and Thomas Kerr (British Columbia Centre for Excellence in HIV/AIDS).  
47  
48  
49  
50  
51

## 52 53 REFERENCES

54  
55 **1. Moatti JP, Vlahov D, Feroni I, et al. Multiple access to sterile syringes for injection**  
56  
57 **drug users: vending machines, needle exchange programs and legal pharmacy sales in**  
58  
59

- Marseille, France. *Eur Addict Res* 2001;7(1):40-5.
2. Fatseas M, Denis C, Serre F, et al. Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy. *AIDS Behav* 2012;16(7):2082-90. doi: 10.1007/s10461-011-0054-4
  3. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. *Current psychiatry report* 2007;9(5):358-64.
  4. Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. *American Journal of Addiction* 2004;13(1):S17-28.
  5. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. *Clin Infect Dis* 2009;49(9):1433-40.
  6. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. *Addiction* 2005;100(11):1690-700.
  7. Weill-Barillet L, Pillonel J, Semaille C, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. *Rev Epidemiol Sante Publique* 2016 doi: 10.1016/j.respe.2015.10.003
  8. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011;378(9791):571-83. doi: S0140-6736(11)61097-0 [pii] 10.1016/S0140-6736(11)61097-0 [published Online First: 2011/08/02]
  9. Murray JM, Law MG, Gao Z, et al. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. *Int J Epidemiol* 2003;32(5):708-14.
  10. Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. *Aids* 2007;21(14):1967-9.
  11. Denis C, Fatseas M, Beltran V, et al. Impact of 20 years harm reduction policy on HIV and HCV among opioid users not in treatment. *Drug and Alcohol Dependence* 2015;146(e261)
  12. Jauffret-Roustide M, Emmanuelli J, Quaglia M, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study. *Subst Use Misuse* 2006;41(10-12):1603-21.
  13. Leon L, Kasereka S, Barin F, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. *Epidemiol Infect* 2017;145(5):895-907. doi: 10.1017/S0950268816002934
  14. de Vos AS, van der Helm JJ, Matser A, et al. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? *Addiction* 2013;108(6):1070-81. doi: 10.1111/add.12125
  15. Cazein F, Pillonel J, Barin F, et al. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. *AIDS* 2016;30(11):1857-8. doi: 10.1097/QAD.0000000000001115
  16. Kerr T, Wood E, Grafstein E, et al. High rates of primary care and emergency department use among injection drug users in Vancouver. *J Public Health (Oxf)* 2005;27(1):62-6. doi: 10.1093/pubmed/fdh189
  17. Salmon AM, Dwyer R, Jauncey M, et al. Injecting-related injury and disease among clients of a supervised injecting facility. *Drug Alcohol Depend* 2009;101(1-2):132-6. doi: 10.1016/j.drugalcdep.2008.12.002
  18. Dwyer R, Topp L, Maher L, et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users.

- 1  
2  
3 *Drug Alcohol Depend* 2009;100(1-2):9-16. doi: 10.1016/j.drugalcdep.2008.08.016
- 4 19. Palmateer NE, Hope VD, Roy K, et al. Infections with spore-forming bacteria in  
5 persons who inject drugs, 2000-2009. *Emerg Infect Dis* 2013;19(1):29-34. doi:  
6 10.3201/eid1901.120044
- 7 20. Potier C, Laprevote V, Dubois-Arber F, et al. Supervised injection services: what has  
8 been demonstrated? A systematic literature review. *Drug Alcohol Depend* 2014;145:48-  
9 68. doi: 10.1016/j.drugalcdep.2014.10.012
- 10 21. Wood E, Tyndall MW, Li K, et al. Do supervised injecting facilities attract higher-  
11 risk injection drug users? *American journal of preventive medicine* 2005;29(2):126-30.  
12 doi: 10.1016/j.amepre.2005.04.011
- 13 22. Wood E, Kerr T, Small W, et al. Changes in public order after the opening of a  
14 medically supervised safer injecting facility for illicit injection drug users. *CMAJ*  
15 2004;171(7):731-4. doi: 10.1503/cmaj.1040774
- 16 23. Marshall BD, Milloy MJ, Wood E, et al. Reduction in overdose mortality after the  
17 opening of North America's first medically supervised safer injecting facility: a  
18 retrospective population-based study. *Lancet* 2011;377(9775):1429-37. doi:  
19 10.1016/S0140-6736(10)62353-7
- 20 24. Jauffret-Roustide M, Pedrono G, Beltzer N. Supervised consumption rooms: the  
21 French Paradox. *Int J Drug Policy* 2013;24(6):628-30. doi: 10.1016/j.drugpo.2013.05.008
- 22 25. Roux P, Le Gall JM, Debrus M, et al. Innovative community-based educational face-  
23 to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious  
24 risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI  
25 intervention study. *Addiction* 2016;111(1):94-106. doi: 10.1111/add.13089
- 26 26. Kerr T, Stoltz JA, Tyndall M, et al. Impact of a medically supervised safer injection  
27 facility on community drug use patterns: a before and after study. *Bmj*  
28 2006;332(7535):220-2.
- 29 27. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons  
30 from the Vancouver injecting drug use study. *AIDS* 1997;11(8):F59-65.
- 31 28. Fry CL, Lintzeris N. Psychometric properties of the Blood-borne Virus  
32 Transmission Risk Assessment Questionnaire (BBV-TRAQ). *Addiction* 2003;98(2):171-8.
- 33 29. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction  
34 Severity Index. *J Subst Abuse Treat* 1992;9(3):199-213.
- 35 30. Denis C, Fatseas M, Beltran V, et al. Usefulness and validity of the modified  
36 Addiction Severity Index: A focus on alcohol, drugs, tobacco, and gambling. *Subst Abuse*  
37 2016;37(1):168-75. doi: 10.1080/08897077.2015.1036334
- 38 31. Rubinsky AD, Dawson DA, Williams EC, et al. AUDIT-C scores as a scaled marker  
39 of mean daily drinking, alcohol use disorder severity, and probability of alcohol  
40 dependence in a U.S. general population sample of drinkers. *Alcohol Clin Exp Res*  
41 2013;37(8):1380-90. doi: 10.1111/acer.12092
- 42 32. Werb D, Garfein R, Kerr T, et al. A socio-structural approach to preventing  
43 injection drug use initiation: rationale for the PRIMER study. *Harm Reduct J*  
44 2016;13(1):25. doi: 10.1186/s12954-016-0114-1
- 45 33. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the  
46 retrospective diagnosis of childhood attention deficit hyperactivity disorder. *Am J*  
47 *Psychiatry* 1993;150(6):885-90. doi: 10.1176/ajp.150.6.885
- 48 34. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety:  
49 psychometric properties. *J Consult Clin Psychol* 1988;56(6):893-7.
- 50 35. Brunet A, St-Hilaire A, Jehel L, et al. Validation of a French version of the impact of  
51 event scale-revised. *Can J Psychiatry* 2003;48(1):56-61. doi:  
52 10.1177/070674370304800111
- 53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 36. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective  
4 stress. *Psychosom Med* 1979;41(3):209-18.
- 5 37. Dubois B, Slachevsky A, Litvan I, et al. The FAB: a Frontal Assessment Battery at  
6 bedside. *Neurology* 2000;55(11):1621-6.
- 7 38. Dubois B, Touchon J, Portet F, et al. ["The 5 words": a simple and sensitive test for  
8 the diagnosis of Alzheimer's disease]. *Presse Med* 2002;31(36):1696-9. [published Online  
9 First: 2002/12/07]
- 10 39. DeBeck K, Kerr T, Bird L, et al. Injection drug use cessation and use of North  
11 America's first medically supervised safer injecting facility. *Drug Alcohol Depend*  
12 2011;113(2-3):172-6. doi: 10.1016/j.drugalcdep.2010.07.023
- 13 40. Holtzman D, Barry V, Ouellet LJ, et al. The influence of needle exchange programs  
14 on injection risk behaviors and infection with hepatitis C virus among young injection  
15 drug users in select cities in the United States, 1994-2004. *Prev Med* 2009;49(1):68-73.  
16 doi: 10.1016/j.ypmed.2009.04.014
- 17 41. Bravo MJ, Royuela L, De la Fuente L, et al. Use of supervised injection facilities and  
18 injection risk behaviours among young drug injectors. *Addiction* 2009;104(4):614-9. doi:  
19 10.1111/j.1360-0443.2008.02474.x
- 20 42. Jauffret-Roustide M, Chollet A, Santos A, et al. Theory versus practice,  
21 bacteriological efficiency versus personal habits: A bacteriological and user  
22 acceptability evaluation of filtering tools for people who inject drugs. *Drug Alcohol Rev*  
23 2017 doi: 10.1111/dar.12564
- 24 43. Gindi RM, Rucker MG, Serio-Chapman CE, et al. Utilization patterns and  
25 correlates of retention among clients of the needle exchange program in Baltimore,  
26 Maryland. *Drug Alcohol Depend* 2009;103(3):93-8. doi:  
27 10.1016/j.drugalcdep.2008.12.018
- 28 44. Carrieri MP, Rey D, Serraino D, et al. Oral contraception and unprotected sex with  
29 occasional partners of women HIV-infected through injection drug use. *AIDS Care*  
30 2006;18(7):795-800.
- 31 45. Wood E, Kerr T, Lloyd-Smith E, et al. Methodology for evaluating Insite: Canada's  
32 first medically supervised safer injection facility for injection drug users. *Harm Reduct J*  
33 2004;1(1):9. doi: 10.1186/1477-7517-1-9
- 34 46. Brisacier AC. Tableau de bord « Traitements de substitution aux opiacés ». Saint-  
35 Denis: OFDT, 2015.
- 36 47. Carrieri MP, Amass L, Lucas GM, et al. Buprenorphine use: the international  
37 experience. *Clin Infect Dis* 2006;43 Suppl 4:S197-215. doi: 10.1086/508184
- 38 48. van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus  
39 incidence rate over two decades in a cohort of drug users. *Eur J Epidemiol*  
40 2007;22(3):183-93. doi: 10.1007/s10654-006-9089-7
- 41 49. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV  
42 transmission in people who inject drugs: systematic review and meta-analysis. *BMJ*  
43 2012;345:e5945. doi: 10.1136/bmj.e5945
- 44 50. Jauffret-Roustide M, Le Strat Y, Couturier E, et al. A national cross-sectional study  
45 among drug-users in France: epidemiology of HCV and highlight on practical and  
46 statistical aspects of the design. *BMC Infect Dis* 2009;9:113.
- 47 51. Strike C, Jairam JA, Kolla G, et al. Increasing public support for supervised  
48 injection facilities in Ontario, Canada. *Addiction* 2014;109(6):946-53. doi:  
49 10.1111/add.12506
- 50 52. De Jong W, Weber U. The professional acceptance of drug use: a closer look at  
51 drug consumption rooms in the Netherlands, Germany and Switzerland.  
52 *International Journal of Drug Policy* 1999;10:99-108.
- 53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 53. Strike C, Watson TM, Kolla G, et al. Ambivalence about supervised injection  
4 facilities among community stakeholders. *Harm Reduct J* 2015;12:26. doi:  
5 10.1186/s12954-015-0060-3
- 6 54. Salmon AM, Thein HH, Kimber J, et al. Five years on: what are the community  
7 perceptions of drug-related public amenity following the establishment of the Sydney  
8 Medically Supervised Injecting Centre? *Int J Drug Policy* 2007;18(1):46-53. doi:  
9 10.1016/j.drugpo.2006.11.010
- 10 55. Kral AH, Wenger L, Carpenter L, et al. Acceptability of a safer injection facility  
11 among injection drug users in San Francisco. *Drug Alcohol Depend* 2010;110(1-2):160-3.  
12 doi: 10.1016/j.drugalcdep.2010.02.009
- 13 56. Jauffret-Roustide M, Cailbault I. Drug consumption rooms: Comparing times,  
14 spaces and actors in issues of social acceptability in French public debate. *International*  
15 *Journal of Drug Policy* 2018;56:208-17. doi: <https://doi.org/10.1016/j.drugpo.2018.04.014>
- 16 57. Kerr T, Tyndall MW, Zhang R, et al. Circumstances of first injection among illicit  
17 drug users accessing a medically supervised safer injection facility. *Am J Public Health*  
18 2007;97(7):1228-30. doi: 10.2105/AJPH.2006.086256
- 19 58. Reddon H, Wood E, Tyndall M, et al. Use of North America's first medically  
20 supervised safer injecting facility among HIV-positive injection drug users. *AIDS Educ*  
21 *Prev* 2011;23(5):412-22. doi: 10.1521/aeap.2011.23.5.412
- 22 59. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection  
23 facility. *CMAJ* 2008;179(11):1143-51. doi: 10.1503/cmaj.080808
- 24 60. Wood E, Tyndall MW, Zhang R, et al. Attendance at supervised injecting facilities  
25 and use of detoxification services. *N Engl J Med* 2006;354(23):2512-4. doi:  
26 10.1056/NEJMc052939
- 27 61. Small W, Wood E, Lloyd-Smith E, et al. Accessing care for injection-related  
28 infections through a medically supervised injecting facility: a qualitative study. *Drug*  
29 *Alcohol Depend* 2008;98(1-2):159-62. doi: 10.1016/j.drugalcdep.2008.05.014
- 30 62. Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the  
31 use of a medically supervised safer injection facility. *J Public Health (Oxf)*  
32 2007;29(1):35-9.
- 33 63. Rachlis B, Lloyd-Smith E, Small W, et al. Harmful microinjecting practices among a  
34 cohort of injection drug users in Vancouver Canada. *Subst Use Misuse* 2010;45(9):1351-  
35 66. doi: 10.3109/10826081003767643
- 36 64. Wood RA, Wood E, Lai C, et al. Nurse-delivered safer injection education among a  
37 cohort of injection drug users: evidence from the evaluation of Vancouver's supervised  
38 injection facility. *Int J Drug Policy* 2008;19(3):183-8.
- 39 65. Hyshka E, Bubela T, Wild TC. Prospects for scaling-up supervised injection facilities  
40 in Canada: the role of evidence in legal and political decision-making. *Addiction*  
41 2013;108(3):468-76. doi: 10.1111/add.12064
- 42 66. Small D. Canada's highest court unchains injection drug users; implications for  
43 harm reduction as standard of healthcare. *Harm Reduct J* 2012;9:34. doi: 10.1186/1477-  
44 7517-9-34
- 45 67. Darke S. Self-report among injecting drug users: a review. *Drug Alcohol Depend*  
46 1998;51(3):253-63; discussion 67-8.
- 47 68. Denis C, Fatseas M, Beltran V, et al. Validity of the self-reported drug use section of  
48 the Addiction Severity Index and associated factors used under naturalistic conditions.  
49 *Subst Use Misuse* 2012;47(4):356-63.
- 50 69. Jauffret-Roustide M, Serebroshkaya D, Chollet A, et al. Comparison of social  
51 profiles, practices and situation toward Hepatitis C among Russian-speaking drug users  
52 in Paris, France, ANRS-Coquelicot Study, 2011-20132017.
- 53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## The impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023683.R2
Article Type:	Protocol
Date Submitted by the Author:	27-Dec-2018
Complete List of Authors:	<p>Auriacombe, Marc; Univ Bordeaux; SANPSY, CNRS USR 3413, Addiction Team</p> <p>Roux, Perrine; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Briand Madrid, Laélia; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Kirchherr, Sébastien; INSERM 1114, University Hospital of Strasbourg, Department of Psychiatry and Addictology</p> <p>Kervran, Charlotte; Univ Bordeaux; SANPSY, CNRS USR 3413, Addiction Team</p> <p>Chauvin, Carole; CERMES3 (INSERM U988/UMR CNRS 8211/EHESS/Paris Descartes University)</p> <p>Gutowski, Marie; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Denis, Cécile; SANPSY, CNRS USR 3413, Addiction Team; University of Pennsylvania Center for Studies of Addiction, Department of Psychiatry</p> <p>Carrieri, Maria Patrizia; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur</p> <p>Lalanne, Laurence; INSERM U1114; Hopitaux universitaires de Strasbourg, Department of Psychiatry and Addictology</p> <p>Jauffret-Roustide, Marie; CERMES3 (INSERM U988/UMR CNRS 8211/EHESS/Paris Descartes University)</p> <p>COSINUS, Study Group</p>
<b>Primary Subject Heading</b>:	Addiction
Secondary Subject Heading:	Health policy
Keywords:	supervised injection facility, risk practices, hepatitis C, longitudinal study, injection, harm reduction



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**TITLE :** The impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.

Auriacombe M<sup>\*1,2,3,4</sup>, Roux P<sup>\*5,6</sup>, Briand Madrid L<sup>5,6</sup>, Kirchherr S<sup>7</sup>, Kervran C<sup>1,2</sup>, Chauvin C<sup>8</sup>, Gutowski M<sup>5,6</sup>, Denis C<sup>2,4</sup>, Carrieri MP<sup>5,6</sup>, Lalanne L<sup>\*7,9</sup>, Jauffret-Roustide M<sup>\*8</sup> and the Cosinus study group

<sup>1</sup> Univ. Bordeaux, Bordeaux, France

<sup>2</sup> Addiction Team (Laboratoire de psychiatrie) / SANPSY, CNRS USR 3413, Bordeaux, France

<sup>3</sup> Pôle Addictologie, CH Charles Perrens and CHU de Bordeaux, Bordeaux, France

<sup>4</sup> Center for Studies of Addiction, Department of psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

<sup>5</sup> Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France

<sup>6</sup> ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France.

<sup>7</sup> INSERM 1114, Department of Psychiatry and Addictology, University Hospital of Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France.

<sup>8</sup> CERMES3 (Inserm U988/UMR CNRS 8211/EHESS/Paris Descartes University), Paris, France.

<sup>9</sup> Department of Psychiatry and Addictology, University Hospital of Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France.

\*equal contribution

1  
2  
3  
4  
5  
6 Corresponding author: Perrine Roux, SESSTIM, IHU Méditerranée Infection, 19-21 boulevard  
7  
8 Jean Moulin, 13005 Marseille, France, [perrine.roux@inserm.fr](mailto:perrine.roux@inserm.fr), +334 13 73 22 78  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ABSTRACT

**Introduction:** The high prevalence of hepatitis C and the persistence of HIV and HCV risk practices in people who inject drugs (PWID) in France underlines the need for innovative prevention interventions. The main objective of this article is to describe the design of the COSINUS cohort study and outline which issues it will explore to evaluate the impact of drug consumption rooms (DCR) on PWID outcomes. Secondary objectives are to assess how DCR a) influence other drug-related practices, such as the transition from intravenous to less risky modes of use, b) reduce drug use frequency/quantity, c) increase access to treatment for addiction and comorbidities (infectious, psychiatric and other), d) improve social conditions, and e) reduce levels of violence experienced and drug-related offenses. COSINUS will also give us the opportunity to investigate the impact of other harm reduction tools in France and their combined effect with DCR on reducing HIV-HCV risk practices. Furthermore, we will be better able to identify PWID needs.

**Methods and analysis:** Enrolment in this prospective multisite cohort study started in June 2016. Overall, 680 PWID in 4 different cities (Bordeaux, Marseilles, Paris and Strasbourg) will be enrolled and followed up for 12 months through face-to-face structured interviews administered by trained staff to all eligible participants at baseline (M0), 3-month (M3), 6-month (M6) and 12-month (M12) follow-up visits. These interviews gather data on socio-demographic characteristics, past and current drug and alcohol consumption, drug-use related practices, access to care and social services, experience of violence (as victims), offenses, other psychosocial issues, and perception and needs about harm reduction interventions and services. Longitudinal data analysis will use a mixed logistic model to assess the impact of individual and structural factors, including DCR attendance and exposure to other harm reduction services, on the main outcome (HIV-HCV risk practices).

**Ethics and dissemination:** This study was reviewed and approved by the institutional review

board of the French institute of medical research and health (opinion number: 14-166). The findings of this cohort study will help to assess the impact of DCR on HIV-HCV risk practices and other psychosocial outcomes and trajectories. Moreover, they will enable health authorities to shape health and harm reduction policies according to PWID needs. Finally, they will also help to improve current harm reduction and therapeutic interventions and to create novel ones.

### Strengths and limitations of this study

- This is the first multisite harm reduction focused cohort of PWID conducted in France.
- The study's findings will help to assess the impact of DCR and other harm reduction services on HIV-HCV risk practices in PWID.
- The findings will also assess the needs of PWID in France by providing a greater understanding of their social conditions, access to prevention and treatment services.
- Non French-speaking PWID are excluded from the cohort so their specific needs are not assessed, they may represent up to 20% of people who attend harm reduction facilities in some sites.

**Word count:** manuscript = 2897

## INTRODUCTION

### Rationale

In France, as elsewhere, people who inject drugs (PWID) faced a dramatic HIV epidemic in the 1990s. In response, the French government's harm reduction policy - which first developed programs for access to sterile injection material in 1987 - extended access in 1994 to include syringe vending machines and the sale of ready-to-use injection kits (Steribox®) in community pharmacies<sup>1</sup>, as well as new state-funded needle exchange programs (NEP)<sup>2</sup>. These public health initiatives were concomitant with opiate maintenance treatment (OMT) programs with methadone (available since 1994) and buprenorphine (available since 1995)<sup>3,4</sup> and highly active antiretroviral therapy (HAART) for HIV-infected individuals.<sup>5</sup> HIV prevalence in PWID dramatically decreased from 40% to 20% in 14 years from 1988 to 2002,<sup>2,6</sup> with a prevalence in 2011 of 10%.<sup>7</sup> An estimated 77% to 85% of opioid-dependent individuals in France are currently treated with OMT.<sup>7</sup>

Despite this progress, and just as in many countries where OMT and NEP are available,<sup>8</sup> the impact of this harm reduction policy on the hepatitis C virus (HCV) epidemic in France has not been as great as that for HIV.<sup>2,9-12</sup> This is because this policy was adopted when HCV prevalence was already too high to be rapidly controlled. In 2011, HCV infection prevalence in the country was 64% among many PWID.<sup>7</sup> HCV incidence was also very high, between 11% and 22%,<sup>13</sup> compared with neighboring countries such as the Netherlands.<sup>14</sup> The delay in implementing an efficient harm reduction policy may explain the persistent high national prevalence of HCV in PWID today.<sup>15</sup> Besides HCV and HIV infections, numerous other physical problems can result from injecting drug use, including soft tissue infections,<sup>16,17</sup> cardiovascular and pulmonary complications,<sup>18</sup> and bacterial and fungal infections.<sup>19</sup> In addition, research on existing drug consumption rooms (DCR) showed that they improve access to primary health care and improve safer injection conditions.<sup>20</sup> By attracting the most

1  
2  
3 marginalized PWID,<sup>21</sup> they also reduce the level of public injection and so the number of used  
4 syringes has dropped in public spaces.<sup>22</sup> Finally, it has also been shown that DCR are effective  
5  
6 in reducing fatal overdoses.<sup>23</sup>  
7  
8  
9

10  
11 Despite the French health authorities' reluctance to open DCR for many years, mostly because  
12 of the country's persistent repressive policy toward drug use and general negative public  
13 opinion,<sup>24</sup> their success in other countries encouraged the French government to reconsider  
14 DCR as a possible additional harm reduction (HR) tool. Two DCR, in Paris and Strasbourg,  
15 were opened in 2016 as part of a 6-year experiment granted on the condition that the health and  
16 social impact of the facilities would be rigorously evaluated. These two DCR accept all PWID  
17 18 years or older and provide the following services: the possibility to administer drugs by  
18 injection (or inhalation in some cases, only for PWID), access to social, medical and psychiatric  
19 consultations, the provision of sterile equipment, the collection and disposal of used injection  
20 equipment, primary care, harm reduction counselling and HCV, HBV and HIV testing. In this  
21 perspective, the COSINUS cohort (COhort to identify Structural and INdividual factors  
22 associated with drug Use) was set up in 2016 to prospectively evaluate the impact of DCR on  
23 the reduction of risk-taking behaviors in PWID.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 The main objective of this article is to describe the design of the COSINUS cohort study and  
42 outline which issues it will explore to evaluate the impact of the DCR on PWID outcomes.  
43  
44

#### 45 Research objectives and hypothesis

46  
47  
48 The main objective of COSINUS is to evaluate the impact of regular DCR use on HIV and  
49 HCV risk practices. The hypothesis is that PWID with regular access to DCR have fewer  
50 practices at risk of HCV and HIV transmission than PWID with no access. It will also  
51 investigate the impact of regular DCR use on access to care. Furthermore, data from COSINUS  
52 will be used to study the impact of other individual (e.g., age, gender, ethnicity, housing) and  
53 structural (e.g., exposure to social services, harm reduction services including education about  
54  
55  
56  
57  
58  
59  
60

safer injection)<sup>25</sup> factors on several outcomes (other risk practices, criminality, current drug use, negative life events, etc. ). More specifically, it will help provide a greater understanding of the combined effect of different harm reduction services on PWID health and risk practices.

## METHODS AND ANALYSIS

### Study design

This prospective, multicenter cohort study, which started in June 2016, will enroll a total of 680 PWID by October 2017 in 4 different French cities with different geographical and health characteristics (Bordeaux, Marseilles, Paris and Strasbourg). The study design and data collection tools were partly inspired by an evaluation of the Vancouver Downtown Eastside DCR (Insite)<sup>26</sup> and the Vancouver Injection Drug User Study.<sup>27</sup> Individual follow-up will last 12 months. PWID in the DCR in Paris and Strasbourg constitute the “treatment” group (hereafter “DCR-exposed”), while PWID already enrolled in harm reduction programs constitute the “control” group (hereafter “DCR-unexposed”). These four cities were chosen because they were all candidates for the opening of DCR when the law permitting experimentation with DCR passed (Public Health Law from January 2016). Data collection consists in face-to-face interviews (each lasting approximately 20 to 35 minutes) administered by a trained interviewer at baseline, 3 months, 6 months and 12 months. Data collection is coordinated by the logistics department of methodology and management (CMG) of ORS PACA – INSERM-IRD UMR1252 (SESSTIM) in Marseilles, under the supervision of the cohort’s four PIs (Marc Auriacombe for Bordeaux, Perrine Roux for Marseilles, Marie Jauffret-Roustide for Paris and Laurence Lalanne-Tongio for Strasbourg), and is managed by each site-investigator. Participants are compensated for their time with 10 euros worth of service vouchers after each of the 4 interviews. The study protocol was approved by the Institutional Review Board (IRB00003888) of the French institute of medical research and health (opinion



number: 14-166).

## Participants

Subjects were eligible if they self-reported injecting illicit drugs except cannabis (heroin, cocaine / crack, amphetamines, ecstasy), and/or prescription drugs (methylphenidate, buprenorphine, benzodiazepines, morphine sulphate, oxycodone, methadone) at least once during the previous month. Participants must be over 18 years old and French-speaking. There are no specific exclusion criteria, except if the PWID does not fulfil the inclusion criteria, for example non French-speaking PWID are excluded. Participants must also provide informed consent to participate in the study. They were recruited mainly in the DCR (in the cities where there is one) and in other harm reduction facilities that currently outreach to PWID likely to attend a DCR if available in each city. This mix of recruitment sites was chosen in order to be able to compare PWID between cities. To avoid duplicate enrollment, the month, year and place of birth are recorded for each participant.

## Measures

The evaluation of DCR is based on the following main outcome: the proportion of participants reporting at least one injection-related HIV-HCV risk practice (sharing of syringes/needles, sharing of other injecting paraphernalia (filter, swab, water, cup, etc.)) in the previous month.

The other variables that will be collected are: sociodemographic characteristics (gender, age, housing, employment, living in a couple, ethnicity, parenthood, social allowances, country of birth); history of drug use (age at first drug use, first injection and related context); current drug and alcohol use (type, frequency, quantity of drugs used, context of drug use, use disorder diagnostic criteria, craving); overdoses and suicide risk; drug use-related HIV-HCV risk practices (injecting, snorting, smoking, sharing and reusing injecting equipment); addiction treatments; DCR attendance; health conditions and access to care and prevention (type and

frequency of care, satisfaction with care, HIV, HCV and HBV screening and self-reported HIV and HCV status, education in injection, other HR services); criminality (illegal activities and experience of prison); negative life events (violence, sexual assault, loss of a relative, etc.); psychosocial assessment (anxiety, ADHD, PTSD, etc.); injection initiation (experience and context); cognitive assessments (GONOGO, mnesic test); sexual health (sexual risk practices, contraception); discrimination and life course (parents, childhood).

This interview questionnaire includes the full version or some items from several already validated questionnaires as follows: i) the Blood-Borne Virus Transmission Risk Assessment (BBV-TRAQ)<sup>28</sup> to evaluate the risk practice; ii) a section of the Addiction Severity Index, which is a multi-dimensional questionnaire which measures drug use based on participants' self-report;<sup>29 30</sup> iii) the Alcohol Use Disorders Identification Test (AUDIT-C) questionnaire to measure alcohol consumption;<sup>31</sup> iv) a set of questions from the PRIMER study to examine injection initiation;<sup>32</sup> v) three validated questionnaires to measure psychiatric outcomes: the 25-item Wender Utah Rating Scale (WURS) for attention-deficit/hyperactivity disorder screening,<sup>33</sup> the Beck Anxiety Inventory to measure anxiety<sup>34</sup> and the Post-traumatic stress event questionnaire;<sup>35 36</sup> vi) finally, two questionnaires measure participants' cognitive ability: the go-no go task<sup>37</sup> and the mnesic test.<sup>38</sup>

Table 1 displays the schedule for each assessment.

Table 1. Summary of data collection at each follow-up visit

	M0	M3	M6	M12
--	----	----	----	-----

Socio-demographic characteristics	X	X	X	X
Socio-economic characteristics	X	X	X	X
History of substance use	X			
Current drug use	X	X	X	X
Alcohol and tobacco use	X	X	X	X
Overdoses and suicidal risk	X		X	X
Drug use-related HIV-HCV risk practices	X	X	X	X
Addiction treatment	X	X	X	X
Health conditions and access to care	X		X	X
Screening for HIV and HCV	X		X	X
Criminality	X	X	X	X
Prison experience	X		X	X
Negative life events	X			X
Initiation injection	X		X	X
HR services user satisfaction	X		X	X
Sexual health		X		
Other practices at risk of dermal contamination		X		
DCR attendance and other services	X	X	X	X
Life course		X		
Attention Deficit Hyperactivity Disorder – ADHD		X		

Anxiety: Beck anxiety inventory			X	
Post-traumatic stress disorder			X	
Discrimination		X		
GONOGO Task		X		X
Mnemonic Test		X		X

### Sample size

The main outcome is the comparison of the percentage of PWID reporting at least one injection-related HIV-HCV risk practice during the previous month between the DCR-exposed and DCR-unexposed groups. The sample size needed was calculated according to this main outcome. Many studies from different countries with DCR have shown that between 30%<sup>39 40</sup> and 60%<sup>41</sup> of users regularly attend them (at least once a week). In the French context, the proportion of PWID reporting at least one injection-related HIV-HCV risk practice varies according to the context and the characteristics of PWID recruited in different studies, from 25%<sup>25</sup> to 50%<sup>42</sup>. We hypothesize 33% of regular (i.e., at least once a week) DCR attending participants will report at least one of these events. Supposing that one third of participants will regularly attend DCR, with an alpha=5 % and a power of 80 %, we need a total of 131 participants in each group. Given an expected attrition rate of 40% after 12 months of follow-up,<sup>43</sup> the sample size is therefore 680 (Paris=250, Marseilles=200, Bordeaux=150, Strasbourg=80).

### Statistical methods

COSINUS was developed to show the impact of DCR on HIV-HCV risk practices. Longitudinal data analysis will use a mixed logistic model to assess the impact of individual factors (sociodemographic, behavioral and cognitive data) and structural factors, including

DCR attendance and exposure to other HR services (access to OMT, social services, education to safer injection, etc.), on the main outcome (reporting at least one injection-related HIV-HCV risk practice during the previous month). Data analysis will be carried out with logistic regression models for qualitative data in two ways, multinomial regression for qualitative data of more than two terms, or linear regression for continuous data. In addition, to study the impact of the combined effect of different services (DCR, education about safe injection, other HR services) on the main outcome, we will use mixed-model regression analysis by adjusting for these different structural factors and other covariates. A Cox model-based approach (or duration models) will be used to study the impact of DCR attendance (or other HR services) for a certain event at a certain time (transition from injection to another mode of use, access to care). To take into account bias due to missing data and loss to follow-up, we will perform sensitivity analyses using the Heckman model, which adjusts for this potential source of statistical bias.<sup>44</sup> Analyses will be performed using several statistical software packages (SPSS v. 12.0, Intercooled Stata® v. 10.0 and SAS; statistical v 10.0).

### Patient and Public Involvement

Although participants did not directly contribute to the design of the study or to the development of the research questions, their needs and preferences were considered throughout the process. Feedback to the participants regarding scientific results, will be organized on each study site.

## DISCUSSION

The COSINUS cohort study is the first in France designed to assess the impact of DCR on HIV-HCV risk practices. It is important to note that DCR in France are seen as an additional tool to existing NEP and OMT programs, as well as the recently education program for safer injecting practices.<sup>25</sup>

1  
2  
3 To date, most of the data published on the effects of DCR are from the Vancouver INSITE  
4 research team,<sup>45</sup> whose work greatly contributed to the preliminary design of our cohort study.  
5  
6 However, the French and Vancouver contexts are very different in terms of substances available  
7  
8 on the black market, access to OMT, sharing practices, sero-prevalence of HIV and HCV, and  
9  
10 harm reduction policy. In France, an estimated 180 000 drug users are currently on OMT,<sup>46</sup>  
11  
12 corresponding to an estimated coverage of 80% in urban areas.<sup>7 25</sup> Two thirds of individuals  
13  
14 receiving OMT are treated with buprenorphine. This figure contrasts with other high-level  
15  
16 income countries, where methadone is more accessible.<sup>47</sup> This high coverage of OMT may have  
17  
18 played a role in decreasing long-term HCV prevalence over recent years.<sup>2 9-11</sup> The decrease in  
19  
20 prevalence of HCV has been slower than that seen for HIV. This reflects the situation in other  
21  
22 European countries such as the Netherlands and Switzerland.<sup>48</sup> Overall, despite high coverage  
23  
24 of prevention and treatment services, HCV prevalence data suggest that PWID – including  
25  
26 those receiving OMT<sup>49</sup> - still have a high risk of transmitting HCV.<sup>15 50</sup> DCR can therefore be  
27  
28 an addition to existing HCV prevention tools by engaging difficult-to-reach PWID in OMT and  
29  
30 safer injection practices.  
31  
32

33  
34  
35 Although there are differences between the French and Vancouver contexts in terms of black  
36  
37 market substance abuse (see above), and despite some heterogeneity across and within the four  
38  
39 different metropolitan areas where our study is being conducted,<sup>7</sup> similarities between the two  
40  
41 contexts exist, specifically regarding reduced access to sterile syringes, low socioeconomic  
42  
43 levels, and a high proportion of PWID injecting in public spaces.<sup>7 42</sup> COSINUS will help us  
44  
45 understand the dynamic of HIV-HCV risk practices at a national level, both in already existing  
46  
47 DCR and in sites providing other HR services. In France, incidence of fatal overdoses among  
48  
49 PWID is low, making it difficult to reduce it significantly over a 12-month period. This could  
50  
51 be related to the national harm reduction policy implemented in the 1990s including access to  
52  
53 OMT<sup>6</sup> and a high level of OMT coverage.<sup>7 46</sup>  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Many prospective studies have tested, evaluated and validated DCR worldwide and have shown  
4 several benefits for public health.<sup>20</sup> Although public opinion on DCR is mixed and has seen  
5 shifting attitudes over time,<sup>24 51</sup> DCR acceptance by drug users and the drug-using community  
6 has been positive to date.<sup>52-55</sup> Any evaluation of DCR needs to take into account the social  
7 environment where DCR are implemented, especially social acceptability by the  
8 neighborhood.<sup>56</sup> DCR facilitate access to needles and provide safer places for users at high risk  
9 both to themselves and to their environment.<sup>41 57 58</sup> They provide hygienic and safe conditions  
10 for intravenous users and staff. They reduce morbidity and mortality associated with overdoses  
11 and with HIV and HCV infections, which is not only beneficial to PWID but increases  
12 healthcare cost-effectiveness.<sup>59</sup> They promote access to opioid dependence treatment<sup>60</sup> and to  
13 prevention interventions related to drug injecting practices.<sup>61 62</sup> However, few existing DCR  
14 provide education programs for safer injection<sup>63</sup> or have a space to inhale drugs. Moreover, data  
15 about the combined effect of DCR with other HR services are sparse. The Canadian experience  
16 has shown the importance of the evaluation process of such a controversial HR tool.<sup>64 65</sup> More  
17 specifically, evidence-based findings from an evaluation process of the DCR “Insite” helped to  
18 advocate against its closure, which was threatened by the Federal Government.<sup>66</sup> The  
19 COSINUS cohort study will not only study the impact of regularly attendance in DCR on HIV-  
20 HCV risk practices in PWID in France, but will also assess the combined effect of DCR together  
21 with other HR services (e.g., education about safer injection, access to OMT, social activities)  
22 on these practices.

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 Some limitations have to be acknowledged. First, all the data collected were self-reported.  
51  
52 Although the use of self-reports may be subject to social desirability bias, studies have shown  
53 their reliability in drug-using populations.<sup>67 68</sup> To control any such bias, we used trained  
54 interviewers independent of the participating harm reduction facilities. In terms of the diversity  
55 of our sample, all the PWID were recruited through easily accessible harm reduction facilities  
56  
57  
58  
59  
60

1  
2  
3 which conduct outreach actions, and which constitute the main contact that the PWID  
4 population has with the health care system. Another limitation is that, due to cost limitations of  
5 our study, we enrolled only French-speaking participants. Further studies are planned to better  
6 investigate the impact of DCRs in all the population of PWID including non French-speaking  
7 PWID that represent around 20% of people who attend DCRs.<sup>69</sup>

8  
9  
10  
11  
12  
13  
14  
15 In addition to evaluating DCR and other HR services, this cohort will be used for a more global  
16 assessment of the needs of the PWID population in terms of access to treatment for addictive  
17 disorders. It will also examine the reasons for not seeking treatment, while identifying users  
18 who may benefit from it. It will help to provide a greater understanding of users' social  
19 conditions, practices, their access to prevention and treatment services, and of the role of  
20 incarceration and violence in this population often excluded from the health care system.

## 21 22 23 24 25 26 27 28 29 30 31 32 ETHICS AND DISSEMINATION

33  
34  
35 This study was approved by the Institutional Review Board (IRB00003888) of the French  
36 institute of medical research and health (opinion number: 14-166). All procedures performed  
37 were in accordance with the 1964 Helsinki declaration and its later amendments. All  
38 participants in the survey gave their informed consent.

39  
40  
41  
42  
43  
44  
45 The results from this cohort will enable health authorities shape health and harm reduction  
46 policies according to PWID needs, as well as improve and create novel harm reduction and  
47 therapeutic interventions. All relevant results will be published in peer-reviewed international  
48 scientific journals and presented at conferences, nationally and internationally.

## 49 50 51 52 53 54 55 56 57 LIST OF ABBREVIATIONS

58  
59  
60 ADHD: Attention Deficit Hyperactivity Disorder



1  
2  
3 CEEI/IRB: Institutional Review Board  
4

5  
6 CMG: the logistics department of methodology and management  
7

8  
9 COSINUS: COhort to identify Structural and INdividual factors associated with drug Use  
10

11  
12 DCR: Drug Consumption Rooms  
13

14  
15 HBV: Hepatitis B Virus  
16

17  
18 HCV: Hepatitis C Virus  
19

20  
21 HIV: Human Immunodeficiency Virus  
22

23  
24 HR: Harm Reduction  
25

26  
27 INSERM: National Institute of Health and Medical Research  
28

29  
30 NEP: Needle Exchange Programs  
31

32  
33 OMT: Opiate Maintenance Treatment  
34

35  
36 PWID: People Who Inject Drugs  
37  
38

## 39 40 DECLARATIONS

### 41 42 Authors' contributions

43  
44  
45 Study conception and design: PC, CD, LL, MA, MJR, PR. Drafting of Manuscript: MA, MJR,  
46  
47 LL, PR, CK, CD drafted the first version of the manuscript. MA, LL, MJR, and PR are the  
48  
49 COSINUS cohort study PIs. SK, LBM, MG, CK, CC are the study-site interviewers and  
50  
51 contributed to improving the design of the study. All authors significantly contributed to the  
52  
53 manuscript and approved the final version.  
54  
55

### 56 57 Funding

58  
59 This work was supported by the French Government Addiction Agency MILDECA (The inter-  
60

1  
2  
3 ministerial mission to fight against drugs and addictive practices). The funding sponsors had  
4 no role in the design of the study and will have no role in data collection, analysis, or  
5 interpretation of the data. They were not involved in the preparation, review, or approval of this  
6 manuscript.  
7  
8  
9  
10  
11

### 12 Competing interests

13  
14  
15 The authors declare that they have nothing to disclose regarding funding or conflict of interest  
16 with respect to this manuscript.  
17  
18

### 19 Acknowledgements

20  
21  
22  
23 Members of the COSINUS scientific committee: Henri-Jean Aubin and Nerkassen Chau  
24 (INSERM U669), Pr Jean-Marie Danion (INSERM U1114 and university hospital of  
25 Strasbourg), Maurice Dematteis (university hospital of Grenoble), Laurent Karila (INSERM  
26 U1000) and Thomas Kerr (British Columbia Centre for Excellence in HIV/AIDS).  
27  
28  
29  
30  
31

32  
33 Members of the Cosinus study group has contributed to the design and/or the monitoring of the  
34 cohort: Auriacombe M, Bertoia G, Briand Madrid L, Carrieri MP, Célérier I, Chauvin C,  
35 Danion JM, Denis C, Grelli N, Gutowski M, Hamelin N, Jauffret-Roustide M, Kervran C,  
36 Kirchherr S, Lalanne L, Le Breton M, Roux P, Vilotitch A.  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 Exclusive Licence

47  
48 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the  
49 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive  
50 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has  
51 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US  
52 Federal Government officers or employees acting as part of their official duties; on a worldwide,  
53 perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees  
54  
55  
56  
57  
58  
59  
60

and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

## REFERENCES

1. Moatti JP, Vlahov D, Feroni I, et al. Multiple access to sterile syringes for injection drug users: vending machines, needle exchange programs and legal pharmacy sales in Marseille, France. *Eur Addict Res* 2001;7(1):40-5.
2. Fatseas M, Denis C, Serre F, et al. Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy. *AIDS Behav* 2012;16(7):2082-90. doi: 10.1007/s10461-011-0054-4
3. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. *Current psychiatry report* 2007;9(5):358-64.
4. Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. *American Journal of Addiction* 2004;13(1):S17-28.
5. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. *Clin Infect Dis* 2009;49(9):1433-40.
6. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. *Addiction* 2005;100(11):1690-700.
7. Weill-Barillet L, Pillonel J, Semaille C, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. *Rev Epidemiol Sante Publique* 2016 doi: 10.1016/j.respe.2015.10.003
8. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011;378(9791):571-83. doi: S0140-6736(11)61097-0 [pii] 10.1016/S0140-6736(11)61097-0 [published Online First: 2011/08/02]

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
9. Murray JM, Law MG, Gao Z, et al. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. *Int J Epidemiol* 2003;32(5):708-14.
10. Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. *Aids* 2007;21(14):1967-9.
11. Denis C, Fatseas M, Beltran V, et al. Impact of 20 years harm reduction policy on HIV and HCV among opioid users not in treatment. *Drug and Alcohol Dependence* 2015;146(e261)
12. Jauffret-Roustide M, Emmanuelli J, Quaglia M, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study. *Subst Use Misuse* 2006;41(10-12):1603-21.
13. Leon L, Kasereka S, Barin F, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. *Epidemiol Infect* 2017;145(5):895-907. doi: 10.1017/S0950268816002934
14. de Vos AS, van der Helm JJ, Matser A, et al. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? *Addiction* 2013;108(6):1070-81. doi: 10.1111/add.12125
15. Cazein F, Pillonel J, Barin F, et al. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. *AIDS* 2016;30(11):1857-8. doi: 10.1097/QAD.0000000000001115
16. Kerr T, Wood E, Grafstein E, et al. High rates of primary care and emergency department use among injection drug users in Vancouver. *J Public Health (Oxf)* 2005;27(1):62-6. doi: 10.1093/pubmed/fdh189
17. Salmon AM, Dwyer R, Jauncey M, et al. Injecting-related injury and disease among clients of a supervised injecting facility. *Drug Alcohol Depend* 2009;101(1-2):132-6. doi: 10.1016/j.drugalcdep.2008.12.002
18. Dwyer R, Topp L, Maher L, et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. *Drug Alcohol Depend* 2009;100(1-2):9-16. doi: 10.1016/j.drugalcdep.2008.08.016
19. Palmateer NE, Hope VD, Roy K, et al. Infections with spore-forming bacteria in persons who inject drugs, 2000-2009. *Emerg Infect Dis* 2013;19(1):29-34. doi: 10.3201/eid1901.120044
20. Potier C, Laprevote V, Dubois-Arber F, et al. Supervised injection services: what has been demonstrated? A systematic literature review. *Drug Alcohol Depend* 2014;145:48-68. doi: 10.1016/j.drugalcdep.2014.10.012
21. Wood E, Tyndall MW, Li K, et al. Do supervised injecting facilities attract higher-risk injection drug users? *American journal of preventive medicine* 2005;29(2):126-30. doi: 10.1016/j.amepre.2005.04.011
22. Wood E, Kerr T, Small W, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. *CMAJ* 2004;171(7):731-4. doi: 10.1503/cmaj.1040774
23. Marshall BD, Milloy MJ, Wood E, et al. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. *Lancet* 2011;377(9775):1429-37. doi: 10.1016/S0140-6736(10)62353-7
24. Jauffret-Roustide M, Pedrono G, Beltzer N. Supervised consumption rooms: the French Paradox. *Int J Drug Policy* 2013;24(6):628-30. doi: 10.1016/j.drugpo.2013.05.008
25. Roux P, Le Gall JM, Debrus M, et al. Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious

- risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study. *Addiction* 2016;111(1):94-106. doi: 10.1111/add.13089
26. Kerr T, Stoltz JA, Tyndall M, et al. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. *Bmj* 2006;332(7535):220-2.
27. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. *AIDS* 1997;11(8):F59-65.
28. Fry CL, Lintzeris N. Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ). *Addiction* 2003;98(2):171-8.
29. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. *J Subst Abuse Treat* 1992;9(3):199-213.
30. Denis C, Fatseas M, Beltran V, et al. Usefulness and validity of the modified Addiction Severity Index: A focus on alcohol, drugs, tobacco, and gambling. *Subst Abuse* 2016;37(1):168-75. doi: 10.1080/08897077.2015.1036334
31. Rubinsky AD, Dawson DA, Williams EC, et al. AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers. *Alcohol Clin Exp Res* 2013;37(8):1380-90. doi: 10.1111/acer.12092
32. Werb D, Garfein R, Kerr T, et al. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. *Harm Reduct J* 2016;13(1):25. doi: 10.1186/s12954-016-0114-1
33. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. *Am J Psychiatry* 1993;150(6):885-90. doi: 10.1176/ajp.150.6.885
34. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol* 1988;56(6):893-7.
35. Brunet A, St-Hilaire A, Jehel L, et al. Validation of a French version of the impact of event scale-revised. *Can J Psychiatry* 2003;48(1):56-61. doi: 10.1177/070674370304800111
36. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. *Psychosom Med* 1979;41(3):209-18.
37. Dubois B, Slachevsky A, Litvan I, et al. The FAB: a Frontal Assessment Battery at bedside. *Neurology* 2000;55(11):1621-6.
38. Dubois B, Touchon J, Portet F, et al. ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. *Presse Med* 2002;31(36):1696-9. [published Online First: 2002/12/07]
39. DeBeck K, Kerr T, Bird L, et al. Injection drug use cessation and use of North America's first medically supervised safer injecting facility. *Drug Alcohol Depend* 2011;113(2-3):172-6. doi: 10.1016/j.drugalcdep.2010.07.023
40. Holtzman D, Barry V, Ouellet LJ, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. *Prev Med* 2009;49(1):68-73. doi: 10.1016/j.ypmed.2009.04.014
41. Bravo MJ, Royuela L, De la Fuente L, et al. Use of supervised injection facilities and injection risk behaviours among young drug injectors. *Addiction* 2009;104(4):614-9. doi: 10.1111/j.1360-0443.2008.02474.x
42. Jauffret-Roustide M, Chollet A, Santos A, et al. Theory versus practice, bacteriological efficiency versus personal habits: A bacteriological and user acceptability evaluation of filtering tools for people who inject drugs. *Drug Alcohol Rev* 2017 doi: 10.1111/dar.12564
43. Gindi RM, Rucker MG, Serio-Chapman CE, et al. Utilization patterns and correlates of retention among clients of the needle exchange program in Baltimore, Maryland. *Drug*



- 1  
2  
3 *Alcohol Depend* 2009;103(3):93-8. doi: 10.1016/j.drugalcdep.2008.12.018
- 4 44. Carrieri MP, Rey D, Serraino D, et al. Oral contraception and unprotected sex with  
5 occasional partners of women HIV-infected through injection drug use. *AIDS Care*  
6 2006;18(7):795-800.
- 7 45. Wood E, Kerr T, Lloyd-Smith E, et al. Methodology for evaluating Insite: Canada's  
8 first medically supervised safer injection facility for injection drug users. *Harm Reduct J*  
9 2004;1(1):9. doi: 10.1186/1477-7517-1-9
- 10 46. Brisacier AC. Tableau de bord « Traitements de substitution aux opiacés ». Saint-  
11 Denis: OFDT, 2015.
- 12 47. Carrieri MP, Amass L, Lucas GM, et al. Buprenorphine use: the international  
13 experience. *Clin Infect Dis* 2006;43 Suppl 4:S197-215. doi: 10.1086/508184
- 14 48. van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence  
15 rate over two decades in a cohort of drug users. *Eur J Epidemiol* 2007;22(3):183-93. doi:  
16 10.1007/s10654-006-9089-7
- 17 49. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV  
18 transmission in people who inject drugs: systematic review and meta-analysis. *BMJ*  
19 2012;345:e5945. doi: 10.1136/bmj.e5945
- 20 50. Jauffret-Roustide M, Le Strat Y, Couturier E, et al. A national cross-sectional study  
21 among drug-users in France: epidemiology of HCV and highlight on practical and  
22 statistical aspects of the design. *BMC Infect Dis* 2009;9:113.
- 23 51. Strike C, Jairam JA, Kolla G, et al. Increasing public support for supervised injection  
24 facilities in Ontario, Canada. *Addiction* 2014;109(6):946-53. doi: 10.1111/add.12506
- 25 52. De Jong W, Weber U. The professional acceptance of drug use: a closer look at  
26 drug consumption rooms in the Netherlands, Germany and Switzerland. *International*  
27 *Journal of Drug Policy* 1999;10:99-108.
- 28 53. Strike C, Watson TM, Kolla G, et al. Ambivalence about supervised injection  
29 facilities among community stakeholders. *Harm Reduct J* 2015;12:26. doi: 10.1186/s12954-015-  
30 0060-3
- 31 54. Salmon AM, Thein HH, Kimber J, et al. Five years on: what are the community  
32 perceptions of drug-related public amenity following the establishment of the Sydney  
33 Medically Supervised Injecting Centre? *Int J Drug Policy* 2007;18(1):46-53. doi:  
34 10.1016/j.drugpo.2006.11.010
- 35 55. Kral AH, Wenger L, Carpenter L, et al. Acceptability of a safer injection facility  
36 among injection drug users in San Francisco. *Drug Alcohol Depend* 2010;110(1-2):160-3.  
37 doi: 10.1016/j.drugalcdep.2010.02.009
- 38 56. Jauffret-Roustide M, Cailbault I. Drug consumption rooms: Comparing times, spaces  
39 and actors in issues of social acceptability in French public debate. *International Journal*  
40 *of Drug Policy* 2018;56:208-17. doi: <https://doi.org/10.1016/j.drugpo.2018.04.014>
- 41 57. Kerr T, Tyndall MW, Zhang R, et al. Circumstances of first injection among illicit  
42 drug users accessing a medically supervised safer injection facility. *Am J Public Health*  
43 2007;97(7):1228-30. doi: 10.2105/AJPH.2006.086256
- 44 58. Reddon H, Wood E, Tyndall M, et al. Use of North America's first medically  
45 supervised safer injecting facility among HIV-positive injection drug users. *AIDS Educ*  
46 *Prev* 2011;23(5):412-22. doi: 10.1521/aeap.2011.23.5.412
- 47 59. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection  
48 facility. *CMAJ* 2008;179(11):1143-51. doi: 10.1503/cmaj.080808
- 49 60. Wood E, Tyndall MW, Zhang R, et al. Attendance at supervised injecting facilities  
50 and use of detoxification services. *N Engl J Med* 2006;354(23):2512-4. doi:  
51 10.1056/NEJMc052939
- 52 61. Small W, Wood E, Lloyd-Smith E, et al. Accessing care for injection-related infections  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 through a medically supervised injecting facility: a qualitative study. *Drug Alcohol*  
4 *Depend* 2008;98(1-2):159-62. doi: 10.1016/j.drugalcdep.2008.05.014  
5  
6 62. Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the  
7 use of a medically supervised safer injection facility. *J Public Health (Oxf)* 2007;29(1):35-9.  
8  
9 63. Rachlis B, Lloyd-Smith E, Small W, et al. Harmful microinjecting practices among a  
10 cohort of injection drug users in Vancouver Canada. *Subst Use Misuse* 2010;45(9):1351-  
11 66. doi: 10.3109/10826081003767643  
12  
13 64. Wood RA, Wood E, Lai C, et al. Nurse-delivered safer injection education among a  
14 cohort of injection drug users: evidence from the evaluation of Vancouver's supervised  
15 injection facility. *Int J Drug Policy* 2008;19(3):183-8.  
16  
17 65. Hyshka E, Bubela T, Wild TC. Prospects for scaling-up supervised injection facilities  
18 in Canada: the role of evidence in legal and political decision-making. *Addiction*  
19 2013;108(3):468-76. doi: 10.1111/add.12064  
20  
21 66. Small D. Canada's highest court unchains injection drug users; implications for harm  
22 reduction as standard of healthcare. *Harm Reduct J* 2012;9:34. doi: 10.1186/1477-7517-9-  
23 34  
24  
25 67. Darke S. Self-report among injecting drug users: a review. *Drug Alcohol Depend*  
26 1998;51(3):253-63; discussion 67-8.  
27  
28 68. Denis C, Fatseas M, Beltran V, et al. Validity of the self-reported drug use section of  
29 the Addiction Severity Index and associated factors used under naturalistic conditions.  
30 *Subst Use Misuse* 2012;47(4):356-63.  
31  
32 69. Jauffret-Roustide M, Serebroshaya D, Chollet A, et al. Comparison of social profiles,  
33 practices and situation toward Hepatitis C among Russian-speaking drug users in Paris,  
34 France, ANRS-Coquelicot Study, 2011-2013, 2017; 14-15: 285-290.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60